Atypical lone pair- π interaction with quinone methides in a series of imido-ferrociphenol anticancer drug candidates

Yong Wang, Pascal Pigeon, Siden Top, Juan Garcia, Claire Troufflard, Ilaria Ciofini, Michael James McGlinchey, Gérard Jaouen

► To cite this version:

Yong Wang, Pascal Pigeon, Siden Top, Juan Garcia, Claire Troufflard, et al.. Atypical lone pair- π interaction with quinone methides in a series of imido-ferrociphenol anticancer drug candidates. *Angewandte Chemie International Edition*, 2019, 58, pp.8421-8425. 10.1002/anie.201902456 . hal-02103918

HAL Id: hal-02103918

<https://hal.sorbonne-universite.fr/hal-02103918>

Submitted on 19 Apr 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Atypical lone pair- π interaction with quinone methides in a series of imido-ferrociphenol anticancer drug candidates

Yong Wang,^{1,2} Pascal Pigeon,^{1,2} Siden Top,² Juan Sanz García,¹ Claire Troufflard,² Ilaria Ciofini,¹ Michael J. McGlinchey,^{*3} Gérard Jaouen.^{*1,2}

¹PSL, Chimie ParisTech, 11 rue Pierre et Marie Curie, F-75005 Paris, France

²Sorbonne Université, UPMC Univ Paris 6, UMR 8232 CNRS, IPCM, place Jussieu, F-75005 Paris, France

³UCD School of Chemistry, University College Dublin, Belfield, Dublin 4, Ireland

E-mail: gerard.jaouen@upmc.fr, michael.mcglinchey@ucd.ie

Abstract:

Ferrociphenols, especially those possessing a heterocycle at the terminus of an aliphatic chain, display strong anticancer activity via a novel redox mechanism that generates active metabolites such as quinone methides (QMs). X-ray crystallography and UV-Vis spectroscopy reveal that the specific lone pair (lp)- π interaction between a carbonyl group of the imide and the quinone motif of the QM plays an important role in the exceptional cytotoxic behaviour of their imido-ferrociphenol precursors. This intramolecular lp- π interaction markedly enhanced the stability of the QMs and lowered the pKa values of the corresponding phenolates. As the first example of such a non-covalent interaction that stabilizes QMs remotely, it not only expands the scope of the lp- π interaction in supramolecular chemistry, but also represents a new mode of stabilization of a QM. This unprecedented application of lp- π interactions in imido-ferrociphenol anticancer drug candidates may also have great potential in drug discovery and organocatalyst design.

TOC

With the goal of circumventing the drawbacks^[1] associated with the widely used coordination complexes of Pt^{2+} , the development of metallodrugs based on transition metal bioorganometallic chemistry has gradually come to the fore.^[2] Amongst the organometallic complexes that can be used as antitumoral agents, those of iron, an abundant and cheap metal, occupy a privileged position, mostly featuring ferrocene, a compact, stable, non-toxic metallocene showing reversible redox properties.^[3] We have established the concept of a possible use of ferrocenes in oncology based on an entirely new foundation exemplified by the so-called ferrocifen family (Fig. 1a), such as **1** and **2**, whose IC_{50} values against triple-negative breast cancer (TNBC) cell lines (MDA-MB-231) are 0.6 and 0.5 μM , respectively. These singular entities possess a redox motif of the [ferrocenyl-ene-phenol] type giving rise to ROS in cancer cells. The initial reversible oxidation of the ferrocenyl antenna permits electronic delocalization leading to selective electrophilic quinone methides (QMs, see below) that induce senescence and/or apoptosis, depending on particular parameters.^[3a]

Fig. 1. (a) Ferrocifen derivatives and corresponding QMs. (b) The lone pair- π (lp- π) interaction geometry. (c) Syntheses of imido-ferrociphenols and their derived QMs.

We have recently reported the functionalization of the alkyl chain of **1** by attaching a terminal hydroxyl substituent^[4] or a heterocyclic group,^[5] as in **3** or **4**. This latter modification resulted in

extremely low IC_{50} values ($IC_{50} = 0.035 \mu M$) on TNBC MDA-MB-231 cells; in addition, for the epithelial ovarian cancer cell lines A2780 and the cisplatin resistant species A2780*cisR* the IC_{50} values were 0.035 and 0.049 μM , respectively. These data encouraged us to seek a rationale for this exceptional antiproliferative effect. The first metabolite obtained either in the chemical (Ag^+) or enzymatic oxidation of **1** in cancer cells is the quinone methide **1-QM**, shown in Fig. 1a, that can react via a 1,8-Michael addition with selective nucleophiles in the cancer cells.^[6] The mechanism of action of **4** may follow the similar pathway to that of **1**.

The lone pair- π (lp- π) interaction, depicted schematically in Fig. 1b, refers to the stabilizing association between a lone pair of electrons and the face of a π system, and was first invoked in 1995 for the stabilization of Z-DNA.^[7] It is now widely recognised as a new supramolecular bond.^[8] Although perhaps counterintuitive, and anticipated to be quite weak, its significance has been noted in biological macromolecules^[9] and host-guest systems^[10]. However, relatively few theoretical and experimental studies have elucidated the strength and nature of lp- π interactions,^[11] mostly on simplified binding systems of two small molecules,^[12] or rigid structures such as triptycene^[13] or dibenzobicyclo[3.2.2]nonane,^[14] as well as virtual applications in medicinal chemistry or organocatalysis.^[15] Gratifyingly, an unprecedented intramolecular lp- π interaction between an oxygen of imide group and the quinone motif in ferrocenyl QMs is reported herein; this specific interaction affects the stability profiles and the pKa values of QMs, and eventually provides an explanation for the exceptional cytotoxicities of their corresponding ferrociphenol precursors.

The molecules **10** through **21** (see Fig. 1c and Table 2), in which the basic ferrocifen skeleton bears a succinimido, glutarimido or phthalimido substituent at the terminus of a three-, four- or five-carbon alkyl chain, and the aryl groups are either mono- or di-phenolic, have been prepared in moderate to high yields via a McMurry coupling followed by displacement of chloride by the appropriate imide under basic conditions. The ferroc-di-phenols **4**, **12** and **14**, and also the ferroc-mono-phenols **16**, **18** and **20**, were initially investigated by a combination of 1H and ^{13}C 2D-NMR techniques (Fig. S11-6).

Typically, NOESY measurements on the *Z* isomer of monophenol **16**, (identified as such by a correlation between H(13/17) in the phenol ring with the protons in the adjacent cyclopentadienyl ring) in which a succinimido substituent is sited at the end of the propyl chain, revealed a strong correlation between the methylene protons of the heterocycle with the phenyl protons at C(8), C(9) and C(10). Likewise, in the phthalimido complex, **20**(*Z*) there is a clear NOE correlation between the protons in the aromatic fragment of the heterocycle and the phenyl protons at C(8), C(9) and C(10).

Fig. 2. X-ray crystal structures of ferrociphenols and QMs. (a) 16(*Z*); (b) 20(*Z*); (c) 4-QM; (d) 12-QM.

Gratifyingly, the X-ray crystal structures of **16**(*Z*), **20**(*Z*) and **14**(*Z*) are in excellent accord with the geometries indicated from their NOESY spectra. As shown in Figs. 2a and 2b (see Fig. SI7 for **14**), the heterocyclic and phenyl rings in **16**(*Z*) deviate from parallelism by only 13.7°, and the vertical distance from the centre of the succinimido ring to the phenyl plane is 3.839 Å. Similarly, in **20**(**14**) the dihedral angles between the phthalimido and aryl rings are 16.5°/(14.8°), and the vertical distances from the centre of the imido ring to the phenyl plane are 3.981/(3.972) Å. Interestingly, in molecules **17** and **11** whereby the alkyl chain has been lengthened to four and five carbons, respectively, there are no obvious NOE correlations between the methylene protons of the succinimido group with the phenol or phenyl rings (Fig. SI8-9). This observation correlates with the X-ray crystal structure of **17** (Fig. SI7) in which the imido substituent is oriented well away from the other aryl rings.

Treatment of the ferrocene-diphenols **4**, **10-15**, with silver oxide yielded the corresponding monohydroxy QMs, that were again characterized by utilising the full gamut of 2D techniques.

Surprisingly, at room temperature the NMR data for these QMs were not as well-defined as those derived from the ferrocenyl-monophenols **16-21**; however, at -30 °C well-resolved spectra were obtained, presumably as the result of the slowing of an exchange process (Fig. SI10-11). To rationalize this observation, which is much more evident in concentrated solutions, one can envisage intermolecular proton exchange between the phenolic proton in one hydroxy-QM and the quinone unit in its counterpart. (details see Fig. SI12).

We note in particular that the propyl chain systems (**4-QM**, **12-QM**, **14-QM**) exhibited a markedly greater stability in acetone-*d*₆ than did their counterpart QMs with four (**10-QM**, **13-QM**, **15-QM**) or five (**11-QM**) carbons in the alkyl chain. Indeed, these latter QMs rearranged to the corresponding ferrocenyl-indenes as the sole product in a few days, or occasionally even in a few hours; they were characterized by comparison of their ¹H and ¹³C NMR spectra with previously reported authentic samples (Fig. SI13-19).^[6] In contrast, **4-QM**, **12-QM**, **14-QM** exhibited half-lives in acetone-*d*₆ of at least a week or more, before finally forming multiple products. Evidently, the stability of these QMs, and their ultimate fate, is exquisitely sensitive to the length of the aliphatic chain.

The NOESY spectra of the propyl-chain QMs differ dramatically from those of their ferrociphenol precursors (Fig. SI20-21). Typically, in complex **16-QM**, the correlation between the methylene protons of the succinimido moiety and the adjacent quinone methide ring has been lost; moreover, the methylene group at C(4) is clearly proximate to the protons sited *meta* to the ketone group in the QM ring. These observations are readily rationalized upon examination of the X-ray crystal structure of **4-QM** (Fig. 2) which revealed that the succinimido ring is now oriented almost perpendicular to the quinone methide. The nearer carbonyl oxygen of the succinimido group is positioned 3.250 Å from the plane of the QM ring. Likewise, in **12-QM**, the glutarimido ring adopts an orientation whereby one of its carbonyl oxygens is now 3.278 Å from the plane of the QM ring. There is evidently a clear change in geometry from the precursor ferrociphenols, exemplified by the X-ray data

on **14**, **16** and **20**, in which the structures appear to indicate a π stacking interaction between the almost parallel heterocyclic and adjacent aromatic rings, and those observed for **4-QM** and **12-QM**, in which a carbonyl group is oriented towards the centre of the QM ring. One can most reasonably interpret this result in terms of a lone pair $\cdots$ arene interaction.

The behaviour of the ferrocifenyl QMs under nearly physiological conditions (50 mM phosphate buffer, 37 °C) was conveniently followed by UV-Vis spectroscopy that revealed a distinct colour change from yellow ($\lambda_{\text{max}} \cong 430$ nm) in the neutral species to bright pink ($\lambda_{\text{max}} \cong 560$ nm) in the phenolate form, whereby the negative charge is delocalized over both phenoxy rings (Fig. SI22).^[16] These findings are confirmed by theoretical calculations performed at TDDFT level (Fig. SI23) displaying a significant red-shift after deprotonation and clearly pointing out the involvement of the phenol/phenolate rings in the intense π - π^* transition (Table SI1). Application of the Beer-Lambert Law in conjunction with the Henderson-Hasselbalch equation yielded pK_{a} data (Fig. 3) that clearly showed an increase in the series succinimido < glutarimido < phthalimido. Moreover, these values further increased as the chain was lengthened from propenyl (**4-QM**, **12-QM**, **14-QM**) to butenyl (**11-QM**, **13-QM**, **15-QM**) to pentenyl (**10-QM**). All these values are smaller than the pK_{a} of 9.1 found for **1-QM** which lacks a heterocyclic terminus. We note in particular, the relative ease of deprotonation of those QMs in which there is a lp- π interaction, whereby a carbonyl oxygen is oriented towards the strongly electrophilic quinone methide moiety. These properties are also reflected in their relative stabilities; typically, the half-lives of **4-QM** and **12-QM** are approximately 40 mins at pH 5, whereas **1-QM** and **10-QM** are soon transformed into ferrocenyl-indenes ($t_{1/2}$ is around 10 mins, see Table SI2). One can see clearly that the involvement of lp- π interactions improved the stability profiles of QMs under acidic conditions.

Comp.	pKa	IC ₅₀ (μM) ^a	Comp.	pKa	IC ₅₀ (μM) ^a
1-QM	9.10±0.15	11 ± 0.6	12-QM	8.16±0.07	0.64 ± 0.06
4-QM	7.90±0.12	0.56 ± 0.2	13-QM	8.53±0.10	2.98 ± 0.26
10-QM	8.30±0.12	2.12 ± 0.11	14-QM	8.63±0.01	0.77 ± 0.12
11-QM	8.70±0.02	3.94 ± 0.35	15-QM	8.94±0.03	7.89 ± 0.27

Fig. 3. Acid-base equilibria in the ferrocifenyl-QM systems. The pKa values of QMs (25 μM) were measured at 37 °C in phosphate buffer. The **succinimido**, **glutarimido**, and **phthalimido** QMs are arranged in order of increasing chain length (CH₂)_n, where n = 3, 4, 5. (a) Measured after 5 days of culture (mean of two independent experiments ± SD).

Turning now to the bioactivity of the new imido-ferrociphenols, the results of cytotoxicity tests on MDA-MB-231 cancer cells are listed in Table 2. One can see that **4** and **16** each possessing a three-carbon chain and a succinimido ring showed the most potent cytotoxicity. Replacement of the succinimide ring by a glutarimide or phthalimide ring, as in **12**, **18** or **14**, **20**, resulted in significant loss of activity. Even more strikingly, incorporation of additional methylene units from 3 to 4 or 5, as in **4**, **10** and **11**, triggers >10-fold of loss of activity. A similar decrease in cytotoxicity was observed for glutarimido compounds **12**, **13** and phthalimido compounds **14**, **15**. Evidently, the structure activity relationships of ferrociphenol precursors are in excellent accord with the strength of the lp-π interaction of their corresponding QMs based on the observed stability profiles and pKa values. We suggest that the most active molecules are those in which the alkyl chain length is such as to position a carbonyl of the heterocycle proximate to the quinone motif of corresponding QMs.

Table 2. IC₅₀ values for selected ferrocenyl compounds towards MDA-MB-231 cells.

Imides	Chain length	Ferrociphenols	IC ₅₀ (μM) ^a	Ferrocimonophenols	IC ₅₀ (μM) ^a
--------	--------------	----------------	------------------------------------	--------------------	------------------------------------

		R = OH		R = H
3	4 ^b	0.035 ± 0.005	16	0.035 ± 0.015
	4	10	0.3 ± 0.08	17	0.47 ± 0.01
	5	11	0.43 ± 0.07	--	--
3	12	0.07 ± 0.01	18	0.09 ± 0.01
	4	13	0.29 ± 0.01	19	0.53 ± 0.01
3	14 ^b	0.145 ± 0.005	20	0.41 ± 0.01
	4	15	0.78 ± 0.06	21	3.59 ± 0.16

(a) Measured after 5 days of culture (mean of two independent experiments ± SD); (b) Values taken from ref. 24.

The antiproliferative activity of selected QMs was also tested on MDA-MB-231 cells. (Table 1) One might perhaps have anticipated a much weaker effect than was found for the corresponding precursors considering their long-term instability in the assay medium and possible problems of cell penetration. Once again, however, **4-QM** and **12-QM** exhibited stronger cytotoxicity than all the QMs that we have previously reported;^[4, 6, 17] indeed, their cytotoxicity was even comparable to that of some ferrociphenol precursors. This could explain the excellent antitumor activities of **4** and **12** since their QMs may exhibit even more potent antiproliferative effects when formed inside the cell, close to important cell targets.

The antiproliferative effects of the succinimidopropyl-ferrociphenol, **4**, were further evaluated by the National Cancer Institute on the NCI-60 human tumor cell line panel, which consists of approximately 60 cell lines within nine tumor type subpanels.^[18] They were compared to those found for the ethyl-ferrociphenol, **1**, tamoxifen (TAM) and cisplatin (CDDP) (Fig. 4 and Table SI3). The imido complex **4** shows much stronger cytotoxicity than **1** in most types of cancer cells, and its mean GI₅₀ value (around 0.1 μM) is approximately five-fold more potent than that of **1** (around 0.5 μM); of course, they are all much more potent than tamoxifen and cisplatin. Moreover, **4** shows a high potency towards

a wide range of cancer cell lines, with a particularly high activity against leukemia and CNS cancer cell lines.

Fig. 4. Heat map for GI₅₀ values of 4, 1, TAM and CDDP. The cells were treated for 48 h at five concentrations ranging from 0.01 to 100 μ M. GI₅₀, 50% growth inhibition concentration. The deep red color indicates the highest activity, whereas the deep blue color represents the lowest activity.

To gain more data on the lp- π interactions, whose role appears to be of major significance, a computational study was performed and revealed that the energy differences between conformers that do, or do not, display lp- π interactions are extremely small (less than 1 kcal mol⁻¹ in the case of ferrociphenols and corresponding QMs (**4**, **12**, **14**, **16**, **18** and **20**, see Fig. SI24-25). Previous reports on the phenomenon of lp- π interactions also indicated their strength to be in this range.^[7b, 19] The computed values are at the threshold of accuracy expected for the level of theory used in our calculations, thus allowing us only to conclude that these two conformations have to be considered iso-energetic in

acetone solution. In the case of QMs containing a C₄ chain (that is compounds **10**, **13**, **15**, **17**, **19** and **21**, see Fig. SI26-27) the parallel π – π stacked rotamers are found to be more stable, showing once again how delicate is the balance between π stacking and the lone pair ••• arene interaction in solution and in the solid state. It should also be stressed that the use of empirical dispersion corrections (see SI for computational details) may induce an overestimation of the π – π stacked conformer's stability.

These computational results were supplemented by variable-temperature (V-T) NMR data to probe the barrier to rotation about the alkyl-chain—succinimido linkage. Thus, **16-QM** exists as a racemate in the solid state, but in solution at 203 K, as oscillations within the alkyl chain gradually slow on the NMR time-scale, the emerging chiral character of the enantiomers eventually renders each member of the pairs of methylene protons non-equivalent (Fig. SI28). This diastereotopicity also leads to the development of geminal couplings, and consequent appearance of increasing numbers of peaks. The observed barrier to racemization is ~ 11.5 kcal mol^{–1}. Most importantly, however, the symmetry of the methylene units in the backbone of the succinimido moiety is never broken in either the ¹H or ¹³C regime; hence, this rotational barrier in solution is very low, in accord with the DFT calculations. (see Table SI4)

In earlier work, we were able to isolate and structurally characterize several ferrocifenyl-QMs by introducing methyl substituents adjacent to the ketonic function.^[4, 20] In contrast, in **4-QM** and **12-QM** stabilization is apparently provided only by the lp- π interaction which is optimized by the length of the alkyl chain and also the rigidity of the system relative to the ferrociphenol precursors. This brings about a dramatic impact not only on the pK_a values and stability profile, but more importantly on the bioactivity. To the best of our knowledge, this is the first case of an intramolecular lp- π interaction between a carbonyl and a quinone motif; more importantly, it represents the first demonstration of the stabilization of QMs by a remote weak bond interaction. In previous work, this has been accomplished

either by introducing bulky or electron-donating groups within the quinone scaffold, or by formation of a transition metal quinone complex.^[21]

One of the mechanisms that we have previously identified for the cytotoxic effect of ferrocenyl phenols is based on their in situ transformation to electrophilic QMs. The greater cytotoxicity of these new ferrociphenols may be explained, at least partly, by the lp- π enhanced life-time and stability of their QMs, particularly under weakly acidic conditions. This original temporary stabilizing effect generated on the initial key metabolite is relatively modest from an energetic point of view, but its biological consequences appear to be remarkable since it puts a brake on the rapid chemical dispersion of numerous secondary metabolites that we have identified in a closely related series such as **3**.²⁵ Prolonged drug residence times inside the cell, close to important targets, may result in longer-lasting efficacy, an important factor for drug optimisation.^[22] Thus upon oxidative metabolism to QMs, their generation under comparatively mild physiological conditions should allow them to be more aggressively cytotoxic for cancer cells that are known to have a higher level of oxidative stress than normal cells.

The cytotoxicity of a series of imido-ferrociphenols against TNBC cells is shown to correlate strongly with the presence of lp- π interactions in their corresponding QMs. In cases where this phenomenon is evident from X-ray crystallographic and NMR data, the stability profiles and pKa values suggest that enhancement of the QM life-times is a major factor in determining their antiproliferative activity. This research appears to be the first report of the practical utilization of such a lp- π interaction in medicinal chemistry and may have considerable potential in drug discovery. The unprecedented significance of these lp- π interactions in imido-ferrociphenol anticancer drug candidates merits further exploration, and they are currently under preclinical *in vivo* evaluation for treatment of intractable cancers.

Acknowledgements

Y.W. thanks the PGG foundation, PSL University and Feroscan for financial support, and we thank Jrmy Forte and Geoffrey Gontard (IPCM, CNRS UMR 8232) for the X-ray structure determinations, and the National Cancer Institute Developmental Therapeutics Program for *in vitro* testing. I.C. and J.S.G. received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 648558).

Keywords. antitumor agents, non-covalent interactions, bioorganometallics, quinones, ferrocifen.

References

- [1] a) B. Rosenberg, L. Vancamp, *Cancer Research* **1970**, *30*, 1799-&; b) J. J. Wilson, S. J. Lippard, *Chem. Rev.* **2014**, *114*, 4470-4495.
- [2] a) C. G. Hartinger, P. J. Dyson, *Chem. Soc. Rev.* **2009**, *38*, 391-401; b) B. Albada, N. Metzler-Nolte, *Chem. Rev.* **2016**, *116*, 11797-11839; c) S. M. Meier-Menches, C. Gerner, W. Berger, C. G. Hartinger, B. K. Keppler, *Chem. Soc. Rev.* **2018**, *47*, 909-928; d) P. Zhang, P. J. Sadler, *J. Organomet. Chem.* **2017**, *839*, 5-14.
- [3] a) G. Jaouen, A. Vessieres, S. Top, *Chem. Soc. Rev.* **2015**, *44*, 8802-8817; b) M. Patra, G. Gasser, *Nat. Rev. Chem.* **2017**, 0066; c) K. Kowalski, *Coord. Chem. Rev.* **2016**, *317*, 132-156; d) K. D. Mjos, C. Orvig, *Chem. Rev.* **2014**, *114*, 4540-4563.
- [4] Y. Wang, P. Pigeon, S. Top, M. J. McGlinchey, G. Jaouen, *Angew. Chem. Int. Ed.* **2015**, *54*, 10230-10233.
- [5] P. Pigeon, Y. Wang, S. Top, et al, *J. Med. Chem.* **2017**, *60*, 8358-8368.
- [6] Y. Wang, M-A. Richard, S. Top, et al, *Angew. Chem. Int. Ed.* **2016**, *55*, 10431-10434.
- [7] a) M. Egli, R. V. Gessner, *Proc. Nat. Acad. Sci.* **1995**, *92*, 180; b) M. Egli, S. Sarkhel, *Acc. Chem. Res.* **2007**, *40*, 197-205.
- [8] a) T. J. Mooibroek, P. Gamez, J. Reedijk, *CrystEngComm* **2008**, *10*, 1501-1515; b) S. K. Singh, A. Das, *PhysChem ChemPhys* **2015**, *17*, 9596-9612.
- [9] a) M. Chawla, E. Chermak, Q. Zhang, et al, *Nucleic Acids Research* **2017**, *45*, 11019-11032; b) J. Kozelka, *Eur. Biophys. J.* **2017**, *46*, 729-737.
- [10] Q.-Q. Wang, N. Luo, X.-D. Wang, et al, *J. Am. Chem. Soc.* **2017**, *139*, 635-638.
- [11] Z. Badri, C. Foroutan-Nejad, J. Kozelka, R. Marek, *PhysChem ChemPhys* **2015**, *17*, 26183-26190.
- [12] M.-Z. Ao, Z.-q. Tao, H.-X. Liu, D.-Y. Wu, X. Wang, *Comp. Theor. Chem.* **2015**, *1064*, 25-34.
- [13] B. W. Gung, Y. Zou, Z. Xu, et al, *J. Org. Chem.* **2008**, *73*, 689-693.
- [14] W. B. Motherwell, R. B. Moreno, I. Pavlakos, et al, *Angew. Chem. Int. Ed.* **2018**, *57*, 1193-1198.
- [15] A. J. Neel, M. J. Hilton, M. S. Sigman, F. D. Toste, *Nature* **2017**, *543*, 637.
- [16] V. Scalcon, A. Citta, A. Folda, et al, *J. Inorg. Biol. Chem.* **2016**, *165*, 146-151.
- [17] Y. Wang, P. M. Dansette, P. Pigeon, et al, *Chem. Sci.* **2018**, *9*, 70-78.
- [18] R. H. Shoemaker, *Nat. Rev. Cancer* **2006**, *6*, 813.
- [19] B. W. Gung, X. Xue, H. J. Reich, *J. Org. Chem.* **2005**, *70*, 7232-7237.
- [20] D. Hamels, P. M. Dansette, E. A. Hillard, et al, *Angew. Chem. Int. Ed.* **2009**, *48*, 9124-9126.
- [21] S. E. Rokita, *Quinone Methides*, John Wiley & Sons, Hoboken, N.J. **2009**.
- [22] R. A. Copeland, *Nat Rev Drug Discov.* **2015**, *15*, 87.

Supporting Information

Atypical lone pair- π interaction with quinone methides in a series of imido-ferrociphenol anticancer drug candidates

Yong Wang, Pascal Pigeon, Siden Top, Juan Sanz, García, Claire Troufflard, Ilaria Ciofini, Michael J. McGlinchey, Gérard Jaouen.**

Chemical Synthesis

Computational Details

Biological studies

Figures SI1 – SI28

Tables SI1 – SI5

References

Chemical Synthesis

General Synthetic Methods. All reagents and solvents were obtained from commercial suppliers. THF was obtained by distillation from sodium/benzophenone. Thin layer chromatography (TLC) was performed on silica gel 60 GF₂₅₄. Column chromatography was performed on silica gel Merck 60 (40-63 μ m). All NMR experiments (¹H, ¹³C, 2D-) were carried out at room temperature on Bruker 300 and 400 NMR spectrometers. Mass spectrometry was performed with a Nermag R 10-10C spectrometer. HRMS measurements were performed on a Thermo Fischer LTQ-Orbitrap XL apparatus equipped with an electrospray source by IPCM (UMR 8232). Elemental analyses were performed by the microanalysis service of ICSN (Gif sur Yvette, France).

General procedure for the synthesis of chloroalkene ferrociphenols. Titanium chloride was added dropwise to a suspension of zinc powder in dry THF at 10-20 °C. The mixture was heated at reflux for 2 hours. A second solution was prepared by dissolving the ferrocenylalkyl compound and the suitable benzophenone in dry THF. This latter solution was added dropwise to the first solution and then the reflux was continued overnight. After cooling to room temperature, the mixture was stirred with water and dichloromethane. The mixture was acidified with dilute hydrochloric acid until the dark color disappeared, and was then decanted. The aqueous layer was extracted with dichloromethane and the combination of organic layers was dried on magnesium sulfate. After concentration under reduced pressure, the crude product was flash-chromatographed on silica gel column with ethyl acetate/cyclohexane 1/2 as the eluent to afford the chloroalkenes ferrociphenols as orange solids that were used in the next steps without further treatment.

7-chloro-2-ferrocenyl-1,1-bis-(4-hydroxyphenyl)-hept-1-en, 7. This compound was synthesized using the general procedure for chloroalkenes ferrociphenols with titanium chloride (1.97 g, 1.14 mL, 10.4 mmol), zinc powder (1.24 g, 19 mmol), dry THF (100 mL), 6-chloro-1-ferrocenylhexan-1-one (1.0 g, 3.14 mmol) and 4,4'-dihydroxybenzophenone (0.672 g, 3.14 mmol) in dry THF (20 mL). Compound **7** was obtained in a yield of 34%. ¹H NMR (300 MHz, acetone-*d*₆): δ = 1.32-1.72 (m, 6H, CH₂-CH₂-CH₂), 2.57-2.71 (m, 2H, CH₂-C=C), 3.49 (t, *J* = 6.7 Hz, 2H, CH₂Cl), 3.92 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.06 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.12 (s, 5H, Cp), 6.70 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.81 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.87 (d, *J* = 8.5 Hz, 2H, C₆H₄), 7.06 (d, *J* = 8.5 Hz, 2H, C₆H₄), 8.21 (s, 1H, OH), 8.25 (s, 1H, OH). ¹³C NMR (75 MHz, acetone-*d*₆): δ = 27.5 (CH₂), 30.6 (CH₂), 33.0 (CH₂), 35.2 (CH₂), 45.6 (CH₂), 68.6 (2xCH, C₅H₄), 69.8 (5xCH, Cp), 70.0 (2xCH, C₅H₄), 88.5 (C, C₅H₄), 115.7 (2xCH, C₆H₄), 115.8 (2xCH, C₆H₄), 131.3 (2xCH, C₆H₄), 131.8 (2xCH, C₆H₄), 135.1 (C), 137.1 (C), 137.4 (C), 139.2 (C), 156.6 (C), 156.7 (C).

5-chloro-2-ferrocenyl-1-(4-hydroxyphenyl)-1-phenyl-pent-1-ene, 8. This compound was synthesized using the general procedure for chloroalkenes ferrociphenols with titanium chloride (6.73 g, 3.9 mL, 35.5 mmol), zinc

powder (4.15 g, 63.5 mmol), dry THF (250 mL), 4-chloro-1-ferrocenyl-1-butanone (3.09 g, 10.6 mmol) and 4-hydroxybenzophenone (2.11 g, 10.6 mmol) in dry THF (40 mL). Compound **8** was obtained in a yield of 47%. ¹H NMR (300 MHz, acetone-*d*₆): δ = 1.86-2.02 (m, 2H, CH₂), 2.72-2.88 (m, 2H, CH₂), 3.47 and 3.51 (t, *J* = 6.6 Hz, 2H, CH₂), 3.92 and 3.99 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.07 and 4.10 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.14 and 4.15 (s, 5H, Cp), 6.74 and 6.84 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.91 and 7.07 (d, *J* = 8.5 Hz, 2H, C₆H₄), 7.08-7.39 (m, 5H, Ph), 8.25 and 8.29 (s, 1H, OH). ¹³C NMR (75 MHz, acetone-*d*₆): δ = 32.9 and 33.0 (CH₂), 35.2 and 35.3 (CH₂), 45.8 and 45.9 (CH₂Cl), 68.9 (2xCH, C₅H₄), 69.9 (2xCH, C₅H₄ + 5xCH, Cp), 87.7 and 87.8 (C, C₅H₄), 115.9 and 116.0 (2xCH, C₆H₄), 126.9 and 127.0 (CH, Ph), 128.9 and 129.1 (2xCH_{arom}), 130.0 and 130.5 (2xCH_{arom}), 131.2 and 131.6 (2xCH_{arom}), 134.6 and 134.9 (C), 136.3 and 136.7 (C), 139.8 and 139.9 (C), 145.6 and 146.0 (C), 156.7 and 156.8 (C).

6-chloro-2-ferrocenyl-1-(4-hydroxyphenyl)-1-phenylhex-1-en, 9. This compound was synthesized using the general procedure for chloroalkenes ferrociphenols with titanium chloride (36.804 g, 21.32 mL, 194 mmol), zinc powder (15.218 g, 232.8 mmol), dry THF (600 mL), 5-chloro-1-ferrocenyl-1-pentanone (11.82 g, 38.8 mmol) and 4-hydroxybenzophenone (7.691 g, 38.8 mmol) in dry THF (100 mL). Compound **9** was obtained in a yield of 59%. ¹H NMR (300 MHz, acetone-*d*₆): δ = 1.57-1.74 (m, 4H, CH₂-CH₂), 2.58 and 2.65 (t, *J* = 7.4 Hz, 2H, CH₂-C=C), 3.44 and 3.48 (t, *J* = 6.3 Hz, 2H, CH₂Cl), 3.93 and 4.01 (s broad, 2H, C₅H₄), 4.09 and 4.13 (s broad, 2H, C₅H₄), 4.17 and 4.18 (s, 5H, Cp), 6.74 and 6.83 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.91 and 7.07 (d, *J* = 8.5 Hz, 2H, C₆H₄), 7.13-7.38 (m, 5H, Ph). ¹³C NMR (75 MHz, acetone-*d*₆): δ = 28.6 and 28.7 (CH₂), 33.36 and 33.39 (CH₂), 34.48 and 34.53 (CH₂), 45.5 and 45.6 (CH₂Cl), 69.03 and 69.07 (2xCH, C₅H₄), 70.1 and 70.2 (2xCH, C₅H₄ + 5xCH, Cp), 88.2 (C, C₅H₄), 115.88 and 115.92 (2xCH, C₆H₄), 126.9 (CH, Ph), 128.9 and 129.0 (2xCH_{arom}), 130.1 and 130.6 (2xCH_{arom}), 131.3 and 131.7 (2xCH_{arom}), 135.5 and 135.8 (C), 136.5 and 136.8 (C), 139.6 (C), 145.8 and 146.2 (C), 156.7 and 156.8 (C). HRMS (ESI, C₂₈H₂₇ClFeO: [M]⁺) calcd: 470.1094, found: 470.1091.

General procedure for the synthesis of imido-ferrociphenols. A mixture of potassium carbonate, imide and chloroalkene ferrociphenol in dimethylformamide (DMF) was heated under stirring at 80 °C overnight. The mixture was allowed to cool to room temperature, poured into a dilute hydrochloric acid solution, and extracted twice with diethyl ether, then the organic layer was dried on magnesium sulfate and concentrated under reduced pressure. The residue was purified by flash-chromatography on silica gel column with a gradient of ethyl acetate/cyclohexane (1/2 to 2/1) as the eluent and crystallized from the suitable solvent to afford the imides as orange solids.

N-{6-ferrocenyl-7,7-bis-(4-hydroxyphenyl)-hept-6-enyl}succinimide (11). This compound was synthesized using the general procedure for imides starting from chloroalkene ferrociphenol **7** (0.349 g, 0.697 mmol), succinimide (0.138 g, 1.39 mmol), potassium carbonate (0.193 g, 1.39 mmol), DMF (15 mL) to afford **11** in a yield of 31%. ¹H NMR (300 MHz, acetone-*d*₆): δ = 1.15-1.59 (m, 6H, CH₂-CH₂-CH₂), 2.56-2.70 (m, 6H, 2CH₂

succ + CH₂-C=C), 3.36 (t, *J* = 7.2 Hz, 2H, CH₂N), 3.92 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.05 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.11 (s, 5H, Cp), 6.70 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.80 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.87 (d, *J* = 8.5 Hz, 2H, C₆H₄), 7.05 (d, *J* = 8.5 Hz, 2H, C₆H₄), 8.17 (s broad, 1H, OH), 8.20 (s broad, 1H, OH). ¹³C NMR (75 MHz, acetone-*d*₆): δ = 27.6 (CH₂), 28.1 (CH₂), 28.7 (2xCH₂, succinimide), 31.1 (CH₂), 35.3 (CH₂), 38.9 (CH₂), 68.6 (2xCH, C₅H₄), 69.8 (5xCH, Cp), 70.0 (2xCH, C₅H₄), 88.4 (C, C₅H₄), 115.7 (2xCH, C₆H₄), 115.8 (2xCH, C₆H₄), 131.3 (2xCH, C₆H₄), 131.7 (2xCH, C₆H₄), 135.2 (C), 137.2 (C), 137.5 (C), 139.1 (C), 156.5 (C), 156.6 (C), 178.0 (2xC, C=O). IR (ATR, ν cm⁻¹): 1686 (CO). HRMS (ESI, C₃₃H₃₃FeNNaO₄: [M+Na]⁺) calcd: 586.165118, found: 586.1652. Anal. Calcd for C₃₃H₃₃FeNO₄(H₂O): C, 68.16; H, 6.06; N, 2.4. Found: C, 68.17; H, 6.31; N, 2.37.

N-{5-ferrocenyl-6,6-bis-(4-hydroxyphenyl)-hex-5-enyl}glutarimide (13). This compound was synthesized using the general procedure for imides starting from chloroalkene ferrociphenol **6** (1.0 g, 2.05 mmol), glutarimide (0.465 g, 4.1 mmol), potassium carbonate (0.568 g, 4.1 mmol), DMF (60 mL) to afford **13** in a yield of 7%. ¹H NMR (300 MHz, acetone-*d*₆): δ = 1.35-1.49 (m, 4H, CH₂-CH₂), 1.84-1.95 (m, 2H, CH₂), 2.56-2.67 (m, 6H, 2CH₂ glutarimide + CH₂-C=C), 3.60 (t, *J* = 6.8 Hz, 2H, CH₂N), 3.91 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.06 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.13 (s, 5H, Cp), 6.70 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.80 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.86 (d, *J* = 8.5 Hz, 2H, C₆H₄), 7.04 (d, *J* = 8.5 Hz, 2H, C₆H₄), 8.20 (s, 1H, OH), 8.23 (s, 1H, OH). ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 18.0 (CH₂, glutarimide), 28.8 (CH₂), 29.0 (CH₂), 33.3 (2xCH₂, glutarimide), 35.3 (CH₂), 39.5 (CH₂), 68.8 (2xCH, C₅H₄), 70.1 (5xCH, Cp + 2xCH, C₅H₄), 88.5 (C, C₅H₄), 115.8 (2xCH, C₆H₄), 115.9 (2xCH, C₆H₄), 131.3 (2xCH, C₆H₄), 131.8 (2xCH, C₆H₄), 135.4 (C), 137.2 (C), 137.6 (C), 139.2 (C), 156.6 (C), 156.7 (C), 172.0 (2xC, C=O). IR (KBr, ν cm⁻¹): 1649 (CO). HRMS (ESI, C₃₃H₃₃FeNO₄: [M]⁺) calcd: 563.1754, found: 563.1752. Anal. Calcd for C₃₃H₃₃FeNO₄(H₂O)_{0.1}: C, 70.12; H, 5.92; N, 2.47. Found: C, 69.83; H, 6.31; N, 2.19.

N-{5-ferrocenyl-6,6-bis-(4-hydroxyphenyl)-hex-5-enyl}phthalimide (15). This compound was synthesized using the general procedure for imides starting from chloroalkene ferrociphenol **6** (3.693 g, 7.59 mmol), phthalimide (2.232 g, 15.2 mmol), potassium carbonate (2.097 g, 15.2 mmol), DMF (100 mL) to afford **15** in a yield of 94%. Mp : 101 °C. ¹H NMR (300 MHz, acetone-*d*₆): δ = 1.50-1.73 (m, 4H, CH₂-CH₂), 2.72 (t, *J* = 7.6 Hz, 2H, CH₂-C=C), 3.60 (t, *J* = 6.9 Hz, 2H, CH₂N), 3.94 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.07 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.15 (s, 5H, Cp), 6.72 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.73 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.84 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.98 (d, *J* = 8.5 Hz, 2H, C₆H₄), 7.88 (s, 4H, phthalimide), 8.27 (s, 1H, OH), 8.28 (s, 1H, OH). ¹³C NMR (75 MHz, acetone-*d*₆): δ = 28.2 (CH₂), 28.9 (CH₂), 34.6 (CH₂), 38.0 (CH₂), 68.3 (2xCH, C₅H₄), 69.5 (5xCH, Cp), 69.7 (2xCH, C₅H₄), 88.2 (C, C₅H₄), 115.4 (2xCH, C₆H₄), 115.5 (2xCH, C₆H₄), 123.3 (2xCH, phthalimide), 130.9 (2xCH, C₆H₄), 131.4 (2xCH, C₆H₄), 132.8 (2xC), 134.6 (2xCH, phthalimide + C), 136.7 (C), 137.1 (C), 139.1 (C), 156.3 (C), 156.4 (C), 168.4 (2xC, C=O). IR (KBr, ν cm⁻¹): 1700 (CO). MS (EI, 70 eV) *m/z* : 597 [M]⁺, 532 [M-Cp]⁺, 382, 343. HRMS (ESI, C₃₆H₃₁FeNO₄: [M]⁺) calcd: 597.1602, found: 597.1617. Anal. Calcd for C₃₆H₃₁FeNO₄(H₂O)_{0.5}: C, 71.29; H, 5.31; N, 2.31. Found: C, 70.9; H, 5.32; N, 2.26.

N-{4-ferrocenyl-5-(4-hydroxyphenyl)-5-phenyl-pent-4-enyl}succinimide (16). This compound was synthesized using the general procedure for imides starting from chloroalkene ferrociphenol **8** (0.654 g, 1.43 mmol), succinimide (0.426 g, 4.3 mmol), potassium carbonate (0.594 g, 4.3 mmol), DMF (20 mL) to afford **16** in a yield of 84%. ¹H NMR (300 MHz, acetone-*d*₆): δ = 1.67-1.81 (m, 2H, CH₂), 2.50-2.63 (m, 6H, 2CH₂ succ + CH₂-C=C), 3.33 and 3.36 (t, *J* = 6.6 Hz, 2H, CH₂N), 3.86 and 3.93 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.05 and 4.09 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.13 and 4.14 (s, 5H, Cp), 6.72 and 6.82 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.90 and 7.03 (d, *J* = 8.5 Hz, 2H, C₆H₄), 7.05-7.40 (m, 5H, Ph), 8.26 and 8.35 (s, 1H, OH). ¹³C NMR (75 MHz, acetone-*d*₆): δ = 28.6 and 28.7 (2xCH₂, succ), 29.9 (CH₂), 32.9 and 33.0 (CH₂), 38.9 and 39.0 (CH₂), 68.7 and 68.9 (2xCH, C₅H₄), 69.9 and 70.1 (5xCH, Cp + 2xCH, C₅H₄), 87.5 and 87.6 (C, C₅H₄), 115.9 and 116.0 (2xCH, C₆H₄), 126.9 (CH, Ph), 129.0 and 129.1 (2xCH_{arom}), 130.0 and 130.5 (2xCH_{arom}), 131.2 and 131.6 (2xCH_{arom}), 135.1 and 136.6 (C), 135.6 and 136.7 (C), 139.5 (C), 145.8 and 146.0 (C), 156.7 and 156.9 (C), 177.8 and 177.9 (2xC, C=O). IR (ATR, ν cm⁻¹): 1689 (CO). HRMS (ESI, C₃₁H₂₉FeNNaO₃: [M+Na]⁺) calcd: 542.138903, found: 542.1389. Anal. Calcd for C₃₁H₂₉FeNO₃(H₂O)_{0.4}: C, 70.7; H, 5.7; N, 2.65. Found: C, 70.72; H, 5.77; N, 2.42.

N-{5-ferrocenyl-6-(4-hydroxyphenyl)-6-phenyl-hex-5-enyl}succinimide (17). This compound was synthesized using the general procedure for imides starting from chloroalkene ferrociphenol **9** (1.3 g, 2.76 mmol), succinimide (0.547 g, 5.5 mmol), potassium carbonate (0.763 g, 5.5 mmol), DMF (70 mL) to afford **17** in a yield of 59%. ¹H NMR (300 MHz, acetone-*d*₆): δ = 1.36-1.52 (m, 4H, CH₂-CH₂), 2.55-2.72 (m, 6H, 2CH₂ succ + CH₂-C=C), 3.23-3.36 (m, 2H, CH₂N), 3.86 and 3.93 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.04 and 4.08 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.13 and 4.14 (s, 5H, Cp), 6.72 and 6.82 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.89 and 7.05 (d, *J* = 8.5 Hz, 2H, C₆H₄), 7.05-7.37 (m, 5H, Ph), 8.25 and 8.35 (s, 1H, OH). ¹³C NMR (75 MHz, acetone-*d*₆): δ = 28.5 (CH₂), 28.7 (CH₂), 28.8 (2xCH₂, succ), 35.0 (CH₂), 38.8 (CH₂), 68.9 (2xCH, C₅H₄), 70.0 (5xCH, Cp), 70.2 (2xCH, C₅H₄), 88.0 (C, C₅H₄), 116.0 (2xCH, C₆H₄), 127.0 (CH, Ph), 129.1 (2xCH_{arom}), 130.2 (2xCH_{arom}), 131.8 (2xCH_{arom}), 135.8 (C), 137.0 (C), 139.4 (C), 146.0 (C), 156.9 (C), 178.0 (2xC, C=O). IR (KBr, ν cm⁻¹): 1601 (CO). HRMS (ESI, C₃₂H₃₁FeNO₃: [M]⁺) calcd: 533.1648, found: 533.1645. Anal. Calcd for C₃₂H₃₁FeNO₃: C, 72.05; H, 5.85; N, 2.62. Found: C, 72.08; H, 5.97; N, 2.47.

N-{4-ferrocenyl-5-(4-hydroxyphenyl)-5-phenyl-pent-4-enyl}glutarimide (18). This compound was synthesized using the general procedure for imides starting from chloroalkene ferrociphenol **8** (0.566 g, 1.20 mmol), glutarimide (0.271 g, 2.40 mmol), potassium carbonate (0.332 g, 2.40 mmol), DMF (40 mL) to afford **18** in a yield of 51%. ¹H NMR (300 MHz, acetone-*d*₆): δ = 1.60-1.75 (m, 2H, CH₂), 1.79-1.93 (m, 2H, CH₂), 2.46-2.61 (m, 6H, CH₂ glutarimide + CH₂), 3.56-3.69 (m, 2H, CH₂N), 3.90-4.00 (m, 2H, C₅H₄), 4.04-4.19 (m, 7H, C₅H₄ + Cp), 6.73 and 6.81 (d, *J* = 8.3 Hz, 2H, C₆H₄), 6.92 and 7.02 (d, *J* = 8.3 Hz, 2H, C₆H₄), 7.05-7.39 (m, 5H, Ph), 7.97 (s, 1H, OH). ¹³C NMR (75 MHz, acetone-*d*₆): δ = 17.8 (CH₂, glutarimide), 30.1 (CH₂), 33.0 (CH₂), 33.2 (2xCH₂, glutarimide), 39.6 (CH₂), 68.8 (2xCH, C₅H₄), 70.0 (5xCH, Cp), 70.1 (2xCH, C₅H₄), 87.7 (C, C₅H₄), 115.9 and 116.0 (2xCH, C₆H₄), 126.9 (CH, Ph), 128.9 and 129.1 (2xCH_{arom}), 130.1 and 130.5 (2xCH_{arom}), 131.2

and 131.7 (2xCH_{arom}), 135.2 and 135.6 (C), 136.6 and 136.8 (C), 139.3 (C), 145.8 and 146.1 (C), 156.7 and 156.8 (C), 173.0 (2xC, C=O). IR (KBr, ν cm⁻¹): 1658 (CO). HRMS (ESI, C₃₂H₃₁FeNO₃: [M]⁺) calcd: 533.1648, found: 533.1645. Anal. Calcd for C₃₂H₃₁FeNO₃(H₂O)_{0.1}: C, 71.81; H, 5.87; N, 2.61. Found: C, 72.17; H, 5.91; N, 2.21.

N-{5-ferrocenyl-6-(4-hydroxyphenyl)-6-phenyl-hex-5-enyl}glutarimide (19). This compound was synthesized using the general procedure for imides starting from chloroalkene ferrociphenol **9** (1 g, 2.12 mmol), glutarimide (0.48 g, 4.2 mmol), potassium carbonate (0.587 g, 4.2 mmol), DMF (100 mL) to afford **19** in a yield of 94%. ¹H NMR (300 MHz, acetone-*d*₆): δ = 1.33-1.52 (m, 4H, CH₂-CH₂), 1.87-1.96 (m, 2H, CH₂), 2.57-2.66 (m, 6H, CH₂ glutarimide + CH₂), 3.59 and 3.64 (t, *J* = 6.8 Hz, 2H, CH₂N), 3.87 and 3.94 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.06 and 4.10 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.15 and 4.16 (s, 5H, Cp), 6.74 and 6.83 (d, *J* = 8.6 Hz, 2H, C₆H₄), 6.91 and 7.09 (d, *J* = 8.6 Hz, 2H, C₆H₄), 7.05-7.39 (m, 5H, Ph), 8.21 and 8.24 (s, 1H, OH). ¹³C NMR (75 MHz, acetone-*d*₆): δ = 17.9 (CH₂, glutarimide), 28.8 and 28.9 (CH₂), 29.0 (CH₂), 33.3 (2xCH₂, glutarimide), 35.1 and 35.2 (CH₂), 39.4 and 39.5 (CH₂), 68.8 (2xCH, C₅H₄), 69.90 and 69.93 (5xCH, Cp), 70.0 and 70.1 (2xCH, C₅H₄), 87.89 and 87.94 (C, C₅H₄), 115.9 and 116.0 (2xCH, C₆H₄), 126.8 and 126.9 (2xCH, Ph), 128.9 and 129.0 (2xCH_{arom}), 130.1 and 130.6 (2xCH_{arom}), 131.2 and 131.7 (2xCH_{arom}), 135.8 and 136.1 (C), 136.7 and 137.0 (C), 139.2 and 139.3 (C), 146.0 and 146.3 (C), 156.7 and 156.8 (C), 172.98 and 173.0 (2xC, C=O). IR (KBr, ν cm⁻¹): 1649 (CO). HRMS (ESI, C₃₃H₃₃FeNO₃: [M]⁺) calcd: 547.1804, found: 547.1801. Anal. Calcd for C₃₃H₃₃FeNO₃(AcOEt)_{0.4}: C, 71.31; H, 6.26; N, 2.4. Found: C, 71.49; H, 6.64; N, 2.08.

N-{4-ferrocenyl-5-(4-hydroxyphenyl)-5-phenyl-pent-4-enyl}phthalimide (20). This compound was synthesized using the general procedure for imides starting from chloroalkene ferrociphenol **8** (0.71 g, 1.55 mmol), phthalimide (0.686 g, 4.7 mmol), potassium carbonate (0.644 g, 4.7 mmol), DMF (20 mL) to afford **20** in a yield of 75%. ¹H NMR (300 MHz, acetone-*d*₆): δ = 1.82-1.97 (m, 2H, CH₂), 2.56-2.65 and 2.65-2.74 (m, 2H, CH₂), 3.56 and 3.60 (t, *J* = 6.8 Hz, 2H, CH₂N), 3.84 and 3.93 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.02 and 4.06 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.07 and 4.09 (s, 5H, Cp), 6.67 and 6.70 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.88 and 7.00 (d, *J* = 8.5 Hz, 2H, C₆H₄), 7.02-7.26 (m, 5H, Ph), 7.84 (s, 4H, phthalimide), 8.11 and 8.25 (s, 1H, OH). ¹³C NMR (75 MHz, acetone-*d*₆): δ = 30.4 and 30.7 (CH₂), 33.0 (CH₂), 38.4 (CH₂), 68.8 (2xCH, C₅H₄), 69.9 (5xCH, Cp + 2xCH, C₅H₄), 87.7 and 87.8 (C, C₅H₄), 115.9 (2xCH, C₆H₄), 123.6 and 123.7 (2xCH, phthalimide), 126.7 and 126.9 (CH, Ph), 128.8 and 128.9 (2xCH_{arom}), 129.7 and 130.5 (2xCH_{arom}), 131.0 and 131.6 (2xCH_{arom}), 133.0 and 133.1 (C), 134.8 and 134.9 (2xCH, phthalimide), 135.0 and 135.2 (C), 136.2 and 136.6 (C), 139.6 and 139.7 (C), 145.5 and 146.0 (C), 156.7 and 156.9 (C), 168.7 and 168.8 (2xC, C=O). IR (ATR, ν cm⁻¹): 1697 (CO). HRMS (ESI, C₃₅H₂₉FeNO₃: [M+Na]⁺) calcd: 567.149683, found: 567.1491. Anal. Calcd for C₃₅H₂₉FeNO₃(H₂O)_{0.5}: C, 72.92; H, 5.24; N, 2.42. Found: C, 72.99; H, 5.22; N, 2.25.

N-{5-ferrocenyl-6-(4-hydroxyphenyl)-6-phenyl-hex-5-enyl}phthalimide (21). This compound was synthesized using the general procedure for imides starting from chloroalkene ferrociphenol **9** (1 g, 2.12 mmol), phthalimide

(0.625 g, 4.2 mmol), potassium carbonate (0.587 g, 4.2 mmol), DMF (100 mL) to afford **21** in a yield of 61%. ¹H NMR (300 MHz, acetone-*d*₆): δ = 1.44-1.67 (m, 4H, CH₂-CH₂), 2.64 and 2.70 (t, *J* = 7.7 Hz, 2H, CH₂-C=C), 3.53 and 3.57 (t, *J* = 6.9 Hz, 2H, CH₂N), 3.85 and 3.92 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.02 and 4.05 (t, *J* = 1.9 Hz, 2H, C₅H₄), 4.11 and 4.12 (s, 5H, Cp), 6.71 (d, *J* = 8.5 Hz, 2H, C₆H₄), 6.87 and 7.01 (d, *J* = 8.5 Hz, 2H, C₆H₄), 7.02-7.24 (m, 5H, Ph), 7.85 (s, 4H, phthalimide), 8.17 and 8.19 (s, 1H, OH). ¹³C NMR (75 MHz, acetone-*d*₆): δ = 28.5 (CH₂), 29.2 (CH₂), 34.9 (CH₂), 38.2 and 38.3 (CH₂), 68.7 (2xCH, C₅H₄), 69.8 and 69.9 (5xCH, Cp), 70.0 and 70.1 (2xCH, C₅H₄), 87.9 and 88.0 (C, C₅H₄), 115.8 and 115.9 (2xCH, C₆H₄), 123.6 (2xCH, phthalimide), 126.8 (CH, Ph), 128.8 and 128.9 (2xCH_{arom}), 129.9 and 130.6 (2xCH_{arom}), 131.1 and 131.7 (2xCH_{arom}), 133.1 (2xC), 134.6 (2xCH, phthalimide), 135.6 and 135.9 (C), 136.6 and 136.8 (C), 139.3 and 139.4 (C), 145.8 and 146.2 (C), 156.6 and 156.8 (C), 168.6 and 168.7 (2xC, C=O). IR (KBr, ν cm⁻¹): 1711 (CO). HRMS (ESI, C₃₆H₃₁FeNO₃: [M]⁺) calcd: 581.1648, found: 581.1646.

General procedure for the chemical oxidation of imodo-ferrociphenols to quinone methides. Freshly made Ag₂O¹ was added to a solution of imodo-ferrociphenols in acetone. The dark grey mixture obtained changed to be dark red suspension about 5 minutes later. The reaction was monitored by TLC until complete conversion of the starting material (around 40 minutes). Filtration was followed by removal of the solvent under reduced pressure to give quinone methides as a dark red solid.

Quinone methide 4-QM. Following the general procedure for the oxidation, Ag₂O (0.2 g, 0.9 mmol), compound **4** (0.08 g, 0.15 mmol). Compound **4-QM** was obtained as a dark red solid 75 mg, yield 93%. ¹H NMR (400 MHz, acetone-*d*₆): δ = 2.27 (q, *J* = 7.0 Hz, 2H, CH₂), 2.65 (s, 4H, 2xCH₂), 3.57 (t, *J* = 6.9 Hz, 2H, CH₂), 4.02 (s, 5H, 5xCH; Cp), 4.14 – 4.25 (m, 4H, C₅H₄), 6.34 (m, *J* = 7.5 Hz, 3H, 2xCH+CH), 6.97 (br s, 2H; C₆H₄), 7.39 (br s, 2H; C₆H₄), 7.54 (br s, 2H; C₆H₄), 9.03 (s, 1H, OH). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 28.0 (CH₂), 28.6 (2xCH₂), 37.4 (CH₂), 67.0 (2xCH, C₅H₄), 68.1 (2xCH, C₅H₄), 69.2 (5xCH, Cp), 87.1 (C), 115.4 (2xCH, C₆H₄), 126.7 (CH), 127.8 (C), 128.6 (C), 128.7 (CH; C₆H₄), 132.3 (2xCH; C₆H₄), 133.0 (C), 137.9 (C), 138.9 (CH), 139.4 (2xCH; C₆H₄), 157.1 (C), 177.1 (2C, C=O), 185.9 (C, C=O). HRMS calcd for C₃₁H₂₇FeO₄ (M)⁺: 533.1290, found: 533.1284.

Quinone methide 16-QM. Following the general procedure for the oxidation, Ag₂O (60 mg, 0.3 mmol), compound **16** (25 mg, 0.05 mmol). Compound **16-QM** was obtained as a dark red solid 22 mg, yield 84%. ¹H NMR (400 MHz, acetone-*d*₆): δ = 2.34 (q, *J* = 7.1 Hz, 2H, CH₂), 2.68 (s, 4H, 2xCH₂), 3.61 (t, *J* = 6.9 Hz, 2H, CH₂), 4.00 (s, 5H, 5xCH; Cp), 4.11 (s, 1H, C₅H₄), 4.14 (s, 1H, C₅H₄), 4.19 (s, 1H, C₅H₄), 4.29 (s, 1H, C₅H₄), 6.35 – 6.45 (m, *J* = 7.5 Hz, 3H, 2xCH+CH), 7.45 -7.57 (m, 6H, C₆H₄), 7.65 (dd, *J* = 10.0, 2.7 Hz, 1H, C₆H₄). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 28.0 (CH₂), 28.7 (2xCH₂), 37.4 (CH₂), 68.2 (2xCH, C₅H₄), 69.2 (2xCH, C₅H₄), 69.3 (5xCH, Cp), 86.7 (C), 126.5 (CH), 128.4 (CH), 128.5 (CH), 128.9 (CH), 129.8 (CH), 129.9 (C), 130.7 (CH), 131.1 (CH), 131.1 (CH), 137.4 (CH), 137.8 (C), 138.7 (CH), 139.2 (C), 156.3 (C), 177.4 (2C, C=O), 186.0 (C, C=O). HRMS calcd for C₃₁H₂₇FeO₃ (M)⁺: 517.1340, found: 517.1335.

Quinone methide 10-QM. Following the general procedure for the oxidation, Ag₂O (0.13 g, 0.5 mmol), compound **10** (0.05 g, 0.09 mmol). Compound **10-QM** was obtained as a dark red solid 45 mg, yield 91%. ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.68 (m, *J* = 6.7 Hz, 2H, CH₂), 1.99 (m, 2H, CH₂), 2.60 (s, 4H, 2xCH₂), 3.42 (t, *J* = 6.9 Hz, 2H, CH₂), 4.01 (s, 5H, 5xCH; Cp), 4.10 – 4.20 (m, 4H, C₅H₄), 6.39 (m, *J* = 7.4 Hz, 3H, 2xCH+CH), 6.99 (br s, 2H; C₆H₄), 7.42 (br s, 2H; C₆H₄), 7.58 (br s, 2H; C₆H₄), 9.14 (s, 1H, OH). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 27.1 (CH₂), 27.2 (2xCH₂), 37.7 (CH₂), 66.9 (CH, C₅H₄), 68.0 (2xCH, C₅H₄), 69.1 (CH, C₅H₄), 69.2 (5xCH, Cp), 87.4 (C), 115.4 (2xCH, C₆H₄), 128.6 (2xCH, C₆H₄), 129.6 (2xCH, C₆H₄), 133.2 (C), 136.1 (C), 138.1 (2xCH, C₆H₄), 157.8 (C), 177.1 (2C, C=O), 186.1 (C, C=O). HRMS calcd for C₃₂H₂₉FeO₄ (M)⁺: 547.1446, found: 547.1441. **10-Indene.** ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.05 (m, 1H, CH₂), 1.25 (m, 1H, CH₂), 1.84 (m, 1H, CH₂), 2.07 (m, 1H, CH₂), 2.41 (s, 4H, 2xCH₂), 3.19 (m, 2H, CH₂), 3.71 (m, 1H, CH), 3.87 (s, 5H, 5xCH; Cp), 3.91 (s, 1H, C₅H₄), 3.98 (s, 1H, C₅H₄), 4.09 (s, 1H, C₅H₄), 4.29 (s, 1H, C₅H₄), 6.57 (m, 2H, C₆H₃), 6.82 (s, 1H, C₆H₃), 6.90 (d, *J* = 8.5 Hz 2H; C₆H₄), 7.10 (d, *J* = 8.5 Hz 2H; C₆H₄), 8.09 (s, 1H, OH), 8.45 (s, 1H, OH). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 22.2 (CH₂), 27.8 (2xCH₂), 29.2 (CH₂), 38.2 (CH₂), 49.8 (CH), 66.6 (CH, C₅H₄), 67.8 (CH, C₅H₄), 68.3 (CH, C₅H₄), 68.4 (CH, C₅H₄), 69.2 (5xCH, Cp), 81.0 (C), 110.6 (CH), 113.3 (CH), 115.4 (2xCH, C₆H₄), 119.6 (CH), 128.1 (C), 130.6 (2xCH, C₆H₄), 138.4 (C), 139.6 (C), 148.3 (C), 155.4 (C), 156.8 (C), 177.2 (2C, C=O).

Quinone methide 17-QM. Following the general procedure for the oxidation, Ag₂O (80 mg, 0.4 mmol), compound **17** (40 mg, 0.08 mmol). Compound **17-QM** was obtained as a dark red solid 35 mg, yield 88%. ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.72 (m, 2H, CH₂), 2.09 (m, 2H, CH₂), 2.62 (s, 4H, 2xCH₂), 3.46 (t, *J* = 7.1 Hz, 2H, CH₂), 4.00 (s, 5H, 5xCH; Cp), 4.10 (s, 1H, C₅H₄), 4.15 (s, 1H, C₅H₄), 4.18 (s, 1H, C₅H₄), 4.31 (s, 1H, C₅H₄), 6.37 – 6.44 (m, *J* = 7.5 Hz, 3H, 2xCH+CH), 7.46 – 7.57 (m, 6H, C₆H₄), 7.65 (dd, *J* = 10.2, 2.7 Hz, 1H, C₆H₄). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 26.6 (CH₂), 27.3 (CH₂), 27.9 (2xCH₂), 37.7 (CH₂), 66.7 (2xCH, C₅H₄), 68.1 (2xCH, C₅H₄), 69.3 (5xCH, Cp), 87.0 (C), 128.4 (2xCH, C₆H₄), 128.5 (CH), 128.9 (C), 129.4 (CH), 129.6 (CH), 129.8 (CH), 130.8 (2xCH, C₆H₄), 137.4 (CH), 137.8 (C), 137.9 (C), 138.8 (CH), 156.7 (C), 177.1 (2C, C=O), 186.0 (C, C=O). HRMS calcd for C₃₂H₂₉FeO₃ (M)⁺: 531.1497, found: 531.1491. **17-Indene.** ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.06 (m, 1H, CH₂), 1.26 (m, 1H, CH₂), 1.86 (m, 1H, CH₂), 2.09 (m, 1H, CH₂), 2.41 (s, 4H, 2xCH₂), 3.18 (m, 2H, CH₂), 3.74 (m, 1H, CH), 3.84 (s, 1H, C₅H₄), 3.87 (s, 5H, 5xCH; Cp), 3.99 (s, 1H, C₅H₄), 4.11 (s, 1H, C₅H₄), 4.31 (s, 1H, C₅H₄), 6.53 (m, 2H, C₆H₃), 6.84 (s, 1H, C₆H₃), 7.28 (m, 2H, C₆H₅), 7.34 (d, *J* = 7.5 Hz, 1H; C₆H₅), 7.42 (d, *J* = 7.6 Hz, 2H; C₆H₅), 8.06 (s, 1H, OH). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 22.2 (CH₂), 26.6 (CH₂), 27.8 (2xCH₂), 38.2 (CH₂), 50.0 (CH), 66.7 (CH, C₅H₄), 68.0 (CH, C₅H₄), 68.2 (CH, C₅H₄), 68.6 (CH, C₅H₄), 69.3 (5xCH, Cp), 80.8 (C), 110.6 (CH), 113.4 (CH), 119.5 (CH), 127.3 (CH), 128.5 (CH), 128.6 (2xCH, C₆H₅), 129.5 (2xCH, C₆H₅), 137.4 (C), 138.4 (C), 139.2 (C), 140.1 (C), 148.4 (C), 155.6 (C), 177.2 (2C, C=O).

Quinone methide 12-QM. Following the general procedure for the oxidation, Ag₂O (0.18 g, 0.8 mmol), compound **12** (0.08 g, 0.14 mmol). Compound **12-QM** was obtained as a dark red solid 73 mg, yield 95%. ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.92 (m, 2H), 2.22 (q, *J* = 7.2 Hz, 2H, CH₂), 2.62 (t, *J* = 6.2 Hz, 4H, 2xCH₂),

3.84 (t, $J = 7.1$ Hz, 2H, CH₂), 4.00 (s, 5H, 5xCH; Cp), 4.13 – 4.23 (m, 4H, C₅H₄), 6.31 (t, $J = 7.5$ Hz, 1H, CH), 6.68 (br s, 4H; C₆H₄), 7.49 (d, $J = 7.8$ Hz, 4H; C₆H₄), 9.16 (br s, 1H, OH). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 17.0 (CH₂), 28.4 (CH₂), 32.4 (2xCH₂), 38.1 (CH₂), 66.9 (2xCH, C₅H₄), 68.0 (2xCH, C₅H₄), 69.3 (5xCH, Cp), 87.2 (C), 114.5 (CH, C₆H₄), 115.2 (CH, C₆H₄), 127.0 (2xCH, C₆H₄), 127.9 (CH, C₆H₄), 128.3 (C), 128.8 (CH), 130.6 (C), 133.0 (CH, C₆H₄), 137.8 (C), 138.9 (2xCH, C₆H₄), 139.1 (C), 157.4 (C), 172.3 (2C, C=O), 185.9 (C, C=O). HRMS calcd for C₃₂H₂₉FeO₄ (M)⁺: 547.1446, found: 547.1441.

Quinone methide 18-QM. Following the general procedure for the oxidation, Ag₂O (120 mg, 0.5 mmol), compound **18** (50 mg, 0.1 mmol). Compound **18-QM** was obtained as a dark red solid 45 mg, yield 90%. ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.94 (m, 2H, CH₂), 2.29 (q, $J = 7.6$ Hz, 2H, CH₂), 2.64 (m, 4H, 2xCH₂), 3.89 (td, $J = 6.8, 3.1$ Hz, 2H, CH₂), 3.99 (s, 5H, 5xCH; Cp), 4.13 (m, 2H, C₅H₄), 4.18 (s, 1H, C₅H₄), 4.28 (s, 1H, C₅H₄), 6.31 – 6.46 (m, 3H, 2xCH+CH), 7.43 – 7.61 (m, 6H, C₆H₄), 7.66 (dd, $J = 10.0, 2.7$ Hz, 1H, C₆H₄). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 17.0 (CH₂), 26.6 (2xCH₂), 32.4 (CH₂), 38.1 (CH₂), 68.1 (2xCH, C₅H₄), 69.2 (2xCH, C₅H₄), 69.3 (5xCH, Cp), 86.7 (C), 126.7 (CH), 128.2 (C), 128.4 (2xCH, C₆H₄), 128.5 (CH), 128.9 (CH), 129.7 (CH), 129.9 (CH), 130.7 (2xCH, C₆H₄), 131.1 (C), 137.3 (CH), 137.8 (C), 138.7 (C), 138.8 (CH), 156.3 (C), 172.3 (2C, C=O), 185.9 (C, C=O). HRMS calcd for C₃₂H₂₉FeO₃ (M)⁺: 531.1497, found: 531.1491.

Quinone methide 13-QM. Following the general procedure for the oxidation, Ag₂O (0.05 g, 0.3 mmol), compound **13** (0.03 g, 0.05 mmol). Compound **13-QM** was obtained as a dark red solid 25 mg, yield 89%. ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.65 (m, $J = 7.5$ Hz, 2H, CH₂), 1.88 (m, $J = 6.1$ Hz, 2H, CH₂), 2.59 (t, $J = 6.5$ Hz, 4H, 2xCH₂), 3.72 (t, $J = 6.9$ Hz, 2H, CH₂), 4.03 (s, 5H, 5xCH; Cp), 4.10 – 4.20 (m, 4H, C₅H₄), 6.40 (m, 3H, 2xCH+CH), 7.00 (d, $J = 8.4$ Hz, 2H; C₆H₄), 7.41 (d, $J = 8.0$ Hz, 2H; C₆H₄), 7.58 (d, $J = 10.9$ Hz, 1H; C₆H₄), 7.64 (d, $J = 10.2$ Hz, 1H; C₆H₄), 9.07 (s, 1H, OH). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 17.0 (CH₂), 26.7 (CH₂), 27.5 (CH₂), 32.3 (2xCH₂), 38.3 (CH₂), 66.7 (2xCH, C₅H₄), 68.0 (2xCH, C₅H₄), 69.2 (5xCH, Cp), 87.5 (C), 115.2 (2xCH, C₆H₄), 128.1 (2xCH, C₆H₄), 128.4 (CH, C₆H₄), 129.9 (C), 130.3 (CH, C₆H₄), 132.7 (C), 133.0 (CH, C₆H₄), 137.5 (C), 138.8 (2xCH, C₆H₄), 157.5 (C), 172.1 (2C, C=O), 185.9 (C, C=O). HRMS calcd for C₃₃H₃₁FeO₄ (M)⁺: 561.1603, found: 561.1597. **13-Indene.** ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.19 (m, 1H, CH₂), 1.41 (m, 1H, CH₂), 1.85 (m, $J = 6.6$ Hz, 2H; CH₂), 1.96 (m, 1H, CH₂), 2.23 (m, 1H, CH₂), 2.55 (m, 4H, 2xCH₂), 3.62 (m, 2H, CH₂), 3.81 (m, 1H, CH), 4.01 (s, 5H, 5xCH; Cp), 4.04 (s, 1H, C₅H₄), 4.15 (s, 1H, C₅H₄), 4.22 (s, 1H, C₅H₄), 4.43 (s, 1H, C₅H₄), 6.68 (m, 2H, C₆H₃), 6.97 (s, 1H, C₆H₃), 7.02 (d, $J = 8.5$ Hz, 2H; C₆H₄), 7.22 (d, $J = 8.4$ Hz, 2H; C₆H₄), 8.16 (s, 1H, OH), 8.51 (s, 1H, OH). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 16.9 (CH₂), 23.0 (CH₂), 29.9 (CH₂), 32.4 (2xCH₂), 38.9 (CH₂), 50.1 (CH), 66.6 (CH, C₅H₄), 67.9 (CH, C₅H₄), 68.3 (CH, C₅H₄), 69.2 (5xCH, Cp), 69.5 (CH, C₅H₄), 81.2 (C), 110.6 (CH), 113.2 (CH), 115.4 (2xCH, C₆H₄), 119.6 (CH), 128.1 (C), 130.4 (2xCH, C₆H₄), 139.4 (C), 139.9 (C), 148.6 (C), 155.3 (C), 156.8 (C), 172.2 (2C, C=O).

Quinone methide 19-QM. Following the general procedure for the oxidation, Ag₂O (100 mg, 0.4 mmol), compound **19** (40 mg, 0.07 mmol). Compound **19-QM** was obtained as a dark red solid 38 mg, yield 95%. ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.66 (dt, $J = 14.9, 7.6$ Hz, 2H, CH₂), 1.86 (p, $J = 6.5$ Hz, 2H, CH₂), 2.07 (m, 2H, CH₂), 2.58 (t, $J = 6.5$ Hz, 4H, 2xCH₂), 3.72 (m, 2H, CH₂), 4.00 (s, 5H, 5xCH; Cp), 4.08 (m, 1H, C₅H₄), 4.11 (s,

1H, C₅H₄), 4.17 (s, 1H, C₅H₄), 4.29 (s, 1H, C₅H₄), 6.33 – 6.45 (m, 3H, 2xCH+CH), 7.43 – 7.58 (m, 6H, C₆H₄), 7.64 (dd, *J* = 10.1, 2.7 Hz, 1H, C₆H₄). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 17.0 (CH₂), 27.4 (CH₂), 27.5 (CH₂), 32.4 (2xCH₂), 38.4 (CH₂), 38.1 (CH₂), 66.7 (CH, C₅H₄), 67.1 (CH, C₅H₄), 68.0 (2xCH, C₅H₄), 69.3 (5xCH, Cp), 87.0 (C), 128.4 (2xCH, C₆H₄), 128.5 (CH), 128.9 (CH), 129.6 (C), 129.7 (CH), 129.8 (CH), 130.7 (2xCH, C₆H₄), 137.4 (CH), 137.6 (C), 137.9 (C), 138.9 (CH), 156.7 (C), 172.2 (2C, C=O), 186.0 (C, C=O). HRMS calcd for C₃₃H₃₁FeNO₃ (M)⁺: 545.1653, found: 545.1648. **19-Indene**. ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.11 (m, 1H, CH₂), 1.20 (m, 1H, CH₂), 1.80 (m, 2H, CH₂), 1.89 (m, 1H, CH₂), 2.22 (m, 1H, CH₂), 2.55 (m, 4H, 2xCH₂), 3.60 (m, 2H, CH₂), 3.86 (m, 1H, CH), 3.97 (s, 1H, C₅H₄), 4.02 (s, 5H, 5xCH; Cp), 4.11 (s, 1H, C₅H₄), 4.23 (s, 1H, C₅H₄), 4.43 (s, 1H, C₅H₄), 6.67 (m, 2H, C₆H₃), 6.99 (s, 1H, C₆H₃), 7.39 – 7.59 (m, 5H, C₆H₅), 8.21 (s, 1H, OH). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 16.9 (CH₂), 22.9 (CH₂), 29.9 (CH₂), 32.4 (2xCH₂), 38.9 (CH₂), 50.2 (CH), 66.7 (CH, C₅H₄), 68.0 (CH, C₅H₄), 68.3 (CH, C₅H₄), 68.5 (CH, C₅H₄), 69.3 (5xCH, Cp), 80.8 (C), 110.7 (CH), 113.3 (CH), 119.5 (CH), 127.3 (CH), 128.5 (CH), 128.6 (2xCH, C₆H₅), 129.5 (2xCH, C₆H₅), 137.3 (C), 137.5 (C), 139.1 (C), 140.1 (C), 148.6 (C), 155.5 (C), 172.2 (2C, C=O).

Quinone methide 14-QM. Following the general procedure for the oxidation, Ag₂O (0.25 g, 1 mmol), compound **14** (0.12 g, 0.2 mmol). Compound **14-QM** was obtained as a dark red solid 105 mg, yield 90%. ¹H NMR (400 MHz, acetone-*d*₆): δ = 2.42 (q, *J* = 6.5 Hz, 2H, CH₂), 3.84 (t, *J* = 6.3 Hz, 2H, CH₂), 3.97 (s, 5H, 5xCH; Cp), 4.05 – 4.20 (m, 4H, C₅H₄), 6.02 (br s, 1H, C₆H₄), 6.33 (br s, 1H, C₆H₄), 6.43 (t, *J* = 7.5 Hz, 1H; CH), 6.80 (br s, 2H; C₆H₄), 7.30 (br s, 2H; C₆H₄), 7.47 (br s, 2H; C₆H₄), 7.84 (s, 4H; C₆H₄), 9.02 (s, 1H, OH). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 29.7 (CH₂), 36.9 (CH₂), 68.1 (2xCH, C₅H₄), 69.2 (2xCH, C₅H₄), 69.3 (5xCH, Cp), 87.0 (C), 115.2 (2xCH, C₆H₄), 122.9 (2xCH; C₆H₄), 123.0 (CH; C₆H₄), 123.2 (C), 127.2 (2xCH; C₆H₄), 128.7 (C), 130.7 (C), 132.2 (2xCH; C₆H₄), 132.3 (C), 134.2 (2xCH; C₆H₄), 134.3 (C), 134.5 (C), 139.6 (2xCH; C₆H₄), 156.9 (C), 167.9 (C), 185.7 (C). HRMS calcd for C₃₅H₂₇FeNO₄ (M)⁺: 581.1290, found: 581.1284.

Quinone methide 20-QM. Following the general procedure for the oxidation, Ag₂O (0.25 g, 1 mmol), compound **20** (0.1 g, 0.2 mmol). Compound **20-QM** was obtained as a dark red solid 95 mg, yield 84%. ¹H NMR (400 MHz, acetone-*d*₆): δ = 2.47 (q, *J* = 6.5 Hz, 2H, CH₂), 3.86 (t, *J* = 6.4 Hz, 2H, CH₂), 3.94 (s, 5H, 5xCH; Cp), 4.09 (s, 1H, C₅H₄), 4.11 (s, 1H, C₅H₄), 4.15 (s, 1H, C₅H₄), 4.24 (s, 1H, C₅H₄), 6.06 (dd, *J* = 10.0, 2.0 Hz, 1H, C₆H₄), 6.32 (dd, *J* = 10.1, 2.0 Hz, 1H, C₆H₄), 6.44 (t, *J* = 7.5 Hz, 1H; CH), 7.31 – 7.47 (m, 6H; C₆H₄), 7.50 (dd, *J* = 10.0, 2.7 Hz, 1H, C₆H₄), 7.85 (s, 4H; C₆H₄). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 29.7 (CH₂), 36.9 (CH₂), 68.2 (2xCH, C₅H₄), 69.2 (2xCH, C₅H₄), 69.3 (5xCH, Cp), 86.6 (C), 123.0 (2xCH; C₆H₄), 127.0 (CH; C₆H₄), 128.2 (C), 128.3 (2xCH; C₆H₄), 128.9 (CH; C₆H₄), 129.7 (CH; C₆H₄), 129.9 (C), 130.6 (2xCH; C₆H₄), 131.0 (C), 132.3 (CH; C₆H₄), 134.2 (2xCH; C₆H₄), 134.3 (C), 137.2 (CH; C₆H₄), 137.7 (C), 138.3 (CH; C₆H₄), 139.4 (C), 155.9 (C), 185.7 (C). HRMS calcd for C₃₅H₂₇FeNO₃ (M)⁺: 565.1340, found: 565.1335.

Quinone methide 15-QM. Following the general procedure for the oxidation, Ag₂O (0.15 g, 6 mmol), compound **15** (60 mg, 0.1 mmol). Compound **15-QM** was obtained as a dark red solid 55 mg, yield 92%. ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.83 (m, *J* = 6.7 Hz, 2H, CH₂), 2.06 (m, 2H, CH₂), 3.65 (t, *J* = 6.8 Hz, 2H, CH₂), 4.00 (s, 5H, 5xCH; Cp), 4.05 – 4.20 (m, 4H, C₅H₄), 6.29 (br s, 2H, C₆H₄), 6.42 (t, *J* = 7.5 Hz, 1H; CH),

6.95 (br s, 2H, C₆H₄), 7.40 (br s, 4H; C₆H₄), 7.80 (s, 4H; C₆H₄), 9.17 (s, 1H, OH). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 27.2 (CH₂), 28.0 (CH₂), 37.2 (CH₂), 66.9 (2xCH, C₅H₄), 68.0 (2xCH, C₅H₄), 69.3 (5xCH, Cp), 87.4 (C), 115.5 (2xCH, C₆H₄), 122.7 (C), 122.8 (2xCH; C₆H₄), 123.2 (C), 127.7 (CH; C₆H₄), 128.7 (CH; C₆H₄), 129.4 (2xCH; C₆H₄), 132.1 (2xCH; C₆H₄), 133.0 (C), 134.0 (2xCH; C₆H₄), 134.5 (C), 137.6 (C), 138.1 (CH, C₆H₄), 139.0 (C), 157.5 (C), 167.8 (C), 185.9 (C). HRMS calcd for C₃₆H₂₉FeNO₄ (M)⁺: 595.1446, found: 595.1441. **15-Indene**. ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.37 (m, 1H, CH₂), 1.55 (m, 1H, CH₂), 2.04 (m, 1H, CH₂), 2.30 (m, 1H, CH₂), 3.55 (m, 2H, CH₂), 3.84 (m, 1H, CH), 3.96 (s, 5H, 5xCH; Cp), 4.00 – 4.10 (m, 3H, C₅H₄), 4.33 (s, 1H, C₅H₄), 6.69 (m, 2H, C₆H₃), 6.98 (s, 1H, C₆H₃), 7.03 (d, *J* = 8.5 Hz 2H; C₆H₄), 7.23 (d, *J* = 8.5 Hz 2H; C₆H₄), 7.79 (s, 4H, C₆H₄), 8.23 (s, 1H, OH), 8.62 (s, 1H, OH). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 23.2 (CH₂), 29.2 (CH₂), 37.8 (CH₂), 49.9 (CH), 66.4 (CH, C₅H₄), 67.7 (CH, C₅H₄), 68.3 (CH, C₅H₄), 69.1 (5xCH, Cp), 69.9 (CH, C₅H₄), 80.9 (C), 110.6 (CH), 113.3 (CH), 115.4 (2xCH, C₆H₄), 119.6 (CH), 122.8 (2xCH, C₆H₄), 123.2 (CH), 128.1 (C), 130.6 (2xCH, C₆H₄), 132.2 (C), 133.9 (2xCH, C₆H₄), 134.5 (C), 138.4 (C), 139.6 (C), 148.4 (C), 155.5 (C), 156.8 (C), 167.9 (2C, C=O).

Quinone methide 21-QM. Following the general procedure for the oxidation, Ag₂O (0.15 g, 6 mmol), compound **21** (0.071 g, 0.12 mmol). Compound **21-QM** was obtained as a dark red solid 65 mg, yield 92%. ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.86 (p, *J* = 7.1 Hz, 2H, CH₂), 2.13 (m, 2H, CH₂), 3.68 (t, *J* = 6.9 Hz, 2H, CH₂), 3.97 (s, 5H, 5xCH; Cp), 4.07 (s, 1H, C₅H₄), 4.11 (s, 1H, C₅H₄), 4.16 (s, 1H, C₅H₄), 4.28 (s, 1H, C₅H₄), 6.21 (dd, *J* = 10.1, 1.8 Hz, 1H, C₆H₄), 6.33 (dd, *J* = 10.0, 1.8 Hz, 1H, C₆H₄), 6.44 (t, *J* = 7.5 Hz, 1H; CH), 7.35 (dd, *J* = 10.1, 2.6 Hz, 1H, C₆H₄), 7.45 – 7.51 (m, 5H; C₆H₅), 7.61 (dd, *J* = 10.0, 2.6 Hz, 1H, C₆H₄), 7.81 (m, 4H; C₆H₄). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 27.4 (CH₂), 27.9 (CH₂), 37.2 (CH₂), 68.1 (2xCH, C₅H₄), 69.1 (CH, C₅H₄), 69.3 (5xCH, Cp), 69.5 (CH, C₅H₄), 87.0 (C), 122.8 (2xCH; C₆H₄), 128.2 (C), 128.4 (2xCH; C₆H₄), 128.5 (CH; C₆H₄), 128.8 (CH; C₆H₄), 129.2 (C), 129.7 (CH; C₆H₄), 130.7 (2xCH; C₆H₄), 131.1 (C), 132.1 (C), 134.0 (2xCH; C₆H₄), 137.1 (CH; C₆H₄), 137.9 (CH; C₆H₄), 138.6 (CH; C₆H₄), 156.4 (C), 185.8 (C). HRMS calcd for C₃₆H₂₉FeNO₃ (M)⁺: 579.1497, found: 579.1491.

Quinone methide 11-QM. Following the general procedure for the oxidation, Ag₂O (0.1 g, 4.3 mmol), compound **11** (0.045 g, 0.08 mmol). Compound **11-QM** was obtained as a dark red solid 41 mg, yield 91%. ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.33 (m, 2H, CH₂), 1.41 (m, 2H, CH₂), 1.98 (m, 2H, CH₂), 2.55 (s, 4H, 2xCH₂), 3.28 (t, *J* = 7.0 Hz, 2H, CH₂), 3.90 (s, 5H, 5xCH; Cp), 4.01 (m, 2H, C₅H₄), 4.07 (s, 1H, C₅H₄), 4.17 (s, 1H, C₅H₄), 6.25 (m, *J* = 7.5 Hz, 3H, 2xCH+CH), 6.97 (br s, 2H; C₆H₄), 7.32 (br s, 2H; C₆H₄), 7.50 (br s, 2H; C₆H₄), 9.01 (s, 1H, OH). ¹³C NMR (100 MHz, acetone-*d*₆): δ = 26.2 (CH₂), 26.6 (CH₂), 27.3 (CH₂), 27.9 (2xCH₂), 37.8 (CH₂), 66.7 (CH, C₅H₄), 66.9 (CH, C₅H₄), 68.0 (2xCH, C₅H₄), 69.2 (5xCH, Cp), 87.5 (C), 115.5 (2xCH, C₆H₄), 127.7 (CH), 128.4 (C), 128.6 (CH; C₆H₄), 130.3 (2xCH; C₆H₄), 132.2 (C), 133.1 (CH), 137.7 (2xCH; C₆H₄), 137.8 (C), 139.3 (C), 157.8 (C), 177.1 (2C, C=O), 185.9 (C, C=O). HRMS calcd for C₃₃H₃₁FeO₄ (M)⁺: 561.1603, found: 561.1597. **11-Indene**. ¹H NMR (400 MHz, acetone-*d*₆): δ = 1.04 (m, 1H, CH₂), 1.29 (m, 1H, CH₂), 1.48 (m, 2H, CH₂), 1.89 (m, 1H, CH₂), 2.26 (m, 1H, CH₂), 2.60 (s, 4H, 2xCH₂), 3.34 (m, 2H, CH₂), 3.80 (m, 1H, CH), 4.01 (s, 5H, 5xCH; Cp), 4.07 (s, 1H, C₅H₄), 4.12 (s, 1H, C₅H₄), 4.20 (s, 1H, C₅H₄), 4.42 (s, 1H, C₅H₄), 6.69 (m, 2H,

C₆H₃), 6.97 (s, 1H, C₆H₃), 7.04 (d, $J = 8.5$ Hz 2H; C₆H₄), 7.23 (d, $J = 8.5$ Hz 2H; C₆H₄), 8.18 (s, 1H, OH), 8.55 (s, 1H, OH). ¹³C NMR (100 MHz, acetone-*d*₆): $\delta = 21.6$ (CH₂), 27.6 (CH₂), 27.8 (2xCH₂), 32.5 (CH₂), 37.9 (CH₂), 50.3 (CH), 66.5 (CH, C₅H₄), 67.9 (CH, C₅H₄), 68.2 (CH, C₅H₄), 68.4 (CH, C₅H₄), 69.1 (5xCH, Cp), 81.1 (C), 110.8 (CH), 113.2 (CH), 115.4 (2xCH, C₆H₄), 119.5 (CH), 128.2 (C), 130.6 (2xCH, C₆H₄), 139.3 (C), 139.5 (C), 148.8 (C), 155.3 (C), 156.8 (C), 177.1 (2C, C=O).

Variable-Temperature and decoupling NMR experimental procedures. Variable temperature NMR experiments were performed from 27 °C to -70 °C on a Bruker Avance 400 MHz NMR spectrometer. Data acquisition and processing were performed with TOPSPIN 2.1 program (Bruker). The desired temperature was set on the variable temperature unit and the sample was equilibrated for 10~15 minutes at each set temperature. The ¹H-NMR spectra were recorded using a pulse sequence of proton with a spectral width of 7184 Hz, an acquisition time of 4.5 s and a relaxation delay of 1 s.

The homodecoupling spectra were recorded with the same parameters as that of ¹H-NMR experiments (pulse program name: zgpd). The decoupling power is optimized between 20 dB to 50 dB. Finally, a suitable decoupling power at 35dB was chosen for the experiments as it allows to irradiate the signal of interest without attenuating those nearby. The calculation of energy barrier to this process could be evaluated from peak coalescence according to the following equation: $\Delta G^\ddagger / (R.T_c) = \log_e (\sqrt{2}.R / \pi.N.h) + \log_e (T_c / \delta_\nu)$.

X-ray crystal structure determinations for 14, Z-16, Z-20, 17, E-4-QM and E-12-QM. A single crystal of each compound was selected, mounted onto a cryoloop and transferred into a cold nitrogen gas stream. Intensity data were collected with a Bruker Kappa-APEXII diffractometer using graphite-monochromated Mo-K α radiation ($\lambda = 0.71073$ Å). Data collection was performed with the Bruker APEXII suite. Unit-cell parameters determination, integration and data reduction were carried out with SAINT program. SADABS was used for scaling and absorption corrections. The structures were solved with SHELXT-2014² and refined by full-matrix least-squares methods with SHELXL-2014³ using the WinGX suite⁴ or Olex2 software package⁵. All non-hydrogen atoms were refined anisotropically. The structures were deposited at the Cambridge Crystallographic Data Centre with numbers CCDC 1860092 to 1860097 and can be obtained free of charge via www.ccdc.cam.ac.uk.

Kinetic experiments of selected QMs monitored by UV-Vis spectroscopy. The disappearance of QMs (25 μ M) in 50 mM phosphate buffer (1 mL, pH 7.4, 6.0 or 5.0, 37 °C) was followed by monitoring the decrease in UV absorbance at 430 nm (1 min/scan) using a Cary 50 Scan UV/VIS spectrophotometer. Pseudo first rate constants were determined in duplicate for at least three half-lives.

Measurements of pKa values of selected QMs. By using UV-Vis spectroscopy, one can plot $\log[\text{In-}/\text{HIn}]$ vs. pH and then apply for using Beer-Lambert Law in conjunction with the Henderson-Hasselbalch to calculate for the approximate pKa value of QMs.

$$\text{Log} [\text{In-} / \text{HIn}] = \text{pH} - \text{pKa}$$

Computational Methods

All electronic structure calculations were performed with using the Gaussian program.⁶ Structural optimizations were carried out at Density Functional Theory (DFT) level using the B3LYP exchange correlation functional^{7,8} including an empirical dispersion correction (D3-BJ)⁹ and treating solvent (here acetone) implicitly using the Polarizable Continuum Model (PCM)¹⁰ as implemented in Gaussian. Diffuse-augmented polarization valence-double- ζ (6-31+G(d))¹¹ basis set with one set of d polarization functions,^{12,13} a set of s and p diffuse functions for all atoms but the hydrogens atoms, and the double- ζ quality LANL2DZ¹⁴ basis set with its associated effective core potential¹⁵ (including 10 core electrons) for the iron atom were used. This basis set will be denoted hereafter as 'BS1'. Subsequently, vibrational frequency calculations were performed at the same level of theory in order to confirm that all the structures found were minima. In order to compare the relative stabilities of the different conformers, single point energy calculations were performed on optimized structures at using the Grimme's double-hybrid functional B2PLYP¹⁶ combined with the dispersion correction scheme (D3-BJ)¹⁰ and using the non-empirical double hybrid functional PBE0-DH¹⁷.

For all systems, two different conformers, presenting lp- π interaction or not, were considered.

The UV-Vis absorption spectra of the conformer with the lp- π interaction of the **4-QM**, **12-QM** and **14-QM** compounds (in the phenol protonated and deprotonated form, as shown in Figure 5 of the main text) were computed at Time Dependent-DFT level in acetone using the long-range corrected CAM-B3LYP¹⁸ functional together with the BS1 basis set. The natural transition orbitals¹⁹ (NTO) involved in the most intense low energy transition were computed in order to analyze the nature of the electronic transitions.

Biological studies

Culture cells. Stock solutions (10 mM) of the compounds to be tested were prepared in DMSO and were kept at -20°C in the dark. Serial dilutions in Dulbecco's modified eagle medium (DMEM) without phenol red/Glutamax I were prepared just prior to use. DMEM without phenol red, Glutamax I and fetal bovine serum were purchased from Gibco; MDA-MB-231 cells were obtained from ATCC (Manassas, VA, USA). Cells were maintained in a monolayer culture in DMEM with phenol red/Glutamax I supplemented with 9% fetal bovine serum at 37°C in a 5% CO₂/air-humidified incubator. For proliferation assays, MDA-MB-231 cells were plated in 1 mL of DMEM without phenol red, supplemented with 9% decompemented and hormone-depleted fetal bovine serum, 1% kanamycin, 1% Glutamax I and incubated. The following day (D0), 1 mL of the same medium containing the compounds to be tested was added to the plates. After 3 days (D3) the incubation medium was removed and 2 mL of the fresh medium containing the compounds was added. At different days (D4, D5), the protein content of each well was quantified by methylene blue staining as follows: cell monolayers were fixed for 1 h at room temperature with methylene blue (1mg mL⁻¹ in 50:50 water/MeOH mixture), then washed with water. After addition of HCl (0.1 M, 2 mL), the plate was incubated for 1 h at 37 °C and then the absorbance of each well (4 wells for each concentration) was measured at 655 nm with a Biorad spectrophotometer. The results are

expressed as the percentage of proteins versus the control. Two independent experiments, run in quadruplicate, were performed.

NCI/DTP cytotoxicity tests. The protocol for the determination of cytotoxicity on the 60 cell line panel can be found at https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm; The DTP homepage can be accessed at <http://dtp.cancer.gov/>.

Fig. SI1. 2D-NOESY spectrum of **4** in acetone- d_6 .

Fig. SI2. 2D-NOESY spectrum of **Z-16** in acetone- d_6 .

Fig. SI3. 2D-NOESY spectrum of **12** in acetone- d_6 .

Fig. SI4. 2D-NOESY spectrum of Z-18 in acetone- d_6 .

Fig. SI5. 2D-NOESY spectrum of **14** in acetone- d_6 .

Fig. SI6. 2D-NOESY spectrum of **Z-20** in acetone- d_6 .

Figure SI7. Molecular structure of **14** and **17**, thermal ellipsoids are shown at 50%.

Fig. SI8. 2D-NOESY spectrum of **Z-17** in acetone- d_6 .

Fig. SI9. 2D-NOESY spectrum of **11** in acetone- d_6 .

Fig. SI10. V-T proton spectrum of **4-QM** in acetone- d_6 .

Fig. SI11. V-T carbon spectrum of **4-QM** in acetone- d_6 .

Fig. SI12. Proposed mechanism of interconversion of the neutral QMs and phenolates, and also formation of the ferrocenyl-indenes. The anionic charge so generated can be delocalized over both aryl rings; this also allows rotation about the C(1)-C(2) bond, thereby equilibrating their NMR resonances. Meanwhile, the newly formed cation can be stabilized as a doubly benzylic system in which both aryl substituents possess *para*-hydroxyl substituents. However, over time, decomposition to form a ferrocenyl-indene became evident, a process readily

understood as arising from a cyclization that places the positive charge adjacent to the strongly stabilizing ferrocenyl moiety; subsequent deprotonation yields the observed indenenes.

Fig. SI13. Stability spectrum of **4-QM** in acetone-*d*₆.

Fig. SI14. Stability spectrum of **10-QM** in acetone-*d*₆.

Fig. SI15. Stability spectrum of **11-QM** in acetone-*d*₆.

Fig. SI16. Stability spectrum of **12-QM** in acetone-*d*₆.

Fig. SI17. Stability spectrum of **13-QM** in acetone-*d*₆.

Fig. SI18. Stability spectrum of **14-QM** in $\text{acetone-}d_6$.

Fig. SI19. Stability spectrum of **15-QM** in acetone- d_6 .

Fig. SI20. 2D-NOESY spectrum of *E*-**16-QM** in acetone- d_6 .

Fig. SI21. 2D-NOESY spectrum of *E*-18-QM in acetone- d_6 .

Fig. S122. UV-Vis spectrum of QMs (25 μM) observed in phosphate buffer at 37 $^{\circ}\text{C}$, pH 7.4.

Fig. S123. The UV-Vis absorption spectra of the conformer with the lp- π interaction of the **4-QM**, **12-QM** and **14-QM** compounds (with the phenol protonated and deprotonated, as shown in Figure 5 of the main text) at the CAM-B3LYP/6-31+G* level of theory.

Fig. S124. Relative energies of complexes **4**, **16**, **12**, **18**, **14** and **20**, optimized at the B3LYP/6-31+G* level of theory with the D3-BJ Grimme's dispersion in acetone (PCM). Values in black represent single point calculations performed at the optimized structures at the B2LYPD3/6-31+G* level of theory in acetone (PCM). Values in grey represent single point calculations performed at the optimized structures at the PBEQIDH/6-31+G* level of theory in acetone (PCM). The O-C_{Bz} distances shown in red are more than 4 Å long.

Fig. S125. Relative energies of complexes **4-QM**, **16-QM**, **12-QM**, **18-QM**, **14-QM** and **20-QM**, optimized at the B3LYP/6-31+G* level of theory with the D3-BJ Grimme's dispersion in acetone (PCM). Values in black represent single point calculations performed at the optimized structures at the B2LYPD3/6-31+G* level of theory in acetone (PCM). Values in grey represent single point calculations performed at the optimized structures at the PBEQIDH/6-31+G* level of theory in acetone (PCM).

Fig. SI26. Relative energies of complexes **10**, **17**, **13**, **19**, **15** and **21**, optimized at the B3LYP/6-31+G* level of theory with the D3-BJ Grimme's dispersion in acetone (PCM). Values in black represent single point calculations performed at the optimized structures at the B2LYPD3/6-31+G* level of theory in acetone (PCM). Values in grey represent single point calculations performed at the optimized structures at the PBEQIDH/6-31+G* level of theory in acetone (PCM).

Fig. S127. Relative energies of complexes **10-QM**, **17-QM**, **13-QM**, **19-QM**, **15-QM** and **21-QM**, optimized at the B3LYP/6-31+G* level of theory with the D3-BJ Grimme's dispersion in acetone (PCM). Values in black represent single point calculations performed at the optimized structures at the B2LYPD3/6-31+G* level of theory in acetone (PCM). Values in grey represent single point calculations performed at the optimized structures at the PBEQIDH/6-31+G* level of theory in acetone (PCM).

Fig. SI28. Variable temperature NMR data for **16-QM**. The vinylic proton, H(3), appears as a 7 Hz triplet, while the adjacent methylene group at C(4) is a pseudo-quartet ($J = 7$ Hz) arising from the doublet coupling from H(3) together with a 7 Hz triplet from the methylene protons at C(5); finally, this latter CH₂ unit also appears as a 7 Hz triplet. However, when cooled gradually to 203 K, the methylene protons at C(5) develop quartet character, while its neighbour at C(4) has clearly become a septet, with hints of smaller outer peaks. To simplify the situation, a number of selective proton decoupling experiments were performed on **16-QM** (two magnified insets). Irradiation of the methylene protons at C(4) removed the vicinal coupling to their neighbours at C(5) which now appeared as a singlet; however, at 203 K the protons at C(5) were resolved into a pair of 13 Hz doublets. Analogously, irradiation of the methylene protons at C(5) initially caused the CH₂ group at C(4) to appear as a 7 Hz doublet, but at low temperature it appeared as two pairs of doublets of doublets ($^2J_{\text{HH}} = 14.7$ Hz, $^3J_{\text{HH}} = 7$ Hz).

Table S11. NTOs of the first brightest transition in the TD-DFT spectra for complexes **4-QM**, **12-QM**, **14-QM** and their respective phenolic deprotonated forms.

Complex	Hole	Particle	Nature
4-QM			$\pi \rightarrow \pi^*$
[4-QM]⁻			$\pi \rightarrow \pi^*$
12-QM			$\pi \rightarrow \pi^*$

[12-QM] ⁻			$\pi \rightarrow \pi^*$
14-QM			$\pi \rightarrow \pi^*$
[14-QM] ⁻			$\pi \rightarrow \pi^*$

Table S12. The half-life of selected compounds (25 μ M) measured at 37 °C in phosphate buffer at pH 6.0 and 5.0.

Comp.	T _{1/2} at pH5.0 (mins)	T _{1/2} at pH6.0 (mins)
1-QM	10.9	27.2
4-QM	44.2	203.9
10-QM	13.1	30.5
11-QM	17.3	31.9
12-QM	38.5	113.6
13-QM	19.2	27.3

(a) The rates of disappearance of **QMs** at around 430 nm as described in experimental section.

Table SI3. In Vitro testing results for **4** from the NCI/DTP, data from one experiment shown, maximum concentration: 100 μ M, after 48 h incubation.

National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : D - 791461 / 1			Experiment ID : 1609NS74								Test Type : 08			Units : Molar	
Report Date : October 22, 2016			Test Date : September 06, 2016								QNS :			MC :	
COMI : P722			Stain Reagent : SRB Dual-Pass Related								SSPL : 0Y9M				
Log10 Concentration															
Panel/Cell Line	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.499	2.786	1.870	0.949	0.704	0.496	0.333	60	20	9	-	-33	1.77E-8	8.46E-6	> 1.00E-4
HL-60(TB)	0.513	2.037	1.249	0.647	0.651	0.436	0.438	48	9	9	-15	-15	< 1.00E-8	2.38E-6	> 1.00E-4
K-562	0.201	1.792	1.416	0.910	0.957	0.385	0.172	76	45	48	12	-15	6.73E-8	2.76E-5	> 1.00E-4
MOLT-4	0.545	2.467	1.898	1.040	0.788	0.600	0.356	70	26	13	3	-35	2.86E-8	1.19E-5	> 1.00E-4
RPMI-8226	0.836	2.494	1.813	1.601	1.538	0.672	0.775	59	46	42	-20	-7	4.98E-8	4.82E-6	> 1.00E-4
SR	0.455	1.832	0.995	0.611	0.607	0.378	0.368	39	11	11	-17	-19	< 1.00E-8	2.48E-6	> 1.00E-4
Non-Small Cell Lung Cancer															
A549/ATCC	0.534	2.140	1.669	0.929	0.985	0.794	0.427	71	25	28	16	-20	2.81E-8	2.79E-5	> 1.00E-4
EKVX	0.554	1.693	1.440	1.154	1.072	0.787	0.350	78	53	45	20	-37	2.35E-7	2.28E-5	> 1.00E-4
HOP-62	0.608	1.752	1.384	0.952	0.842	0.797	0.228	68	30	20	16	-63	2.97E-8	1.62E-5	6.95E-5
HOP-92	1.221	1.752	1.462	1.419	1.385	1.260	0.506	45	37	31	7	-59	< 1.00E-8	1.29E-5	7.40E-5
NCI-H226	0.832	2.053	1.937	1.624	1.178	0.914	0.869	90	65	28	7	3	2.55E-7	> 1.00E-4	> 1.00E-4
NCI-H23	0.514	1.762	0.966	0.662	0.696	0.686	0.386	36	12	15	14	-25	< 1.00E-8	2.26E-5	> 1.00E-4
NCI-H322M	0.772	2.015	1.831	1.454	1.407	1.161	0.218	85	55	51	31	-72	1.14E-6	2.01E-5	6.15E-5
NCI-H460	0.270	2.491	1.316	0.504	0.550	0.254	0.117	47	11	13	-6	-57	< 1.00E-8	4.78E-6	7.39E-5
NCI-H522	0.886	2.210	1.757	1.599	1.654	1.167	0.316	66	54	58	21	-64	1.65E-6	1.77E-5	6.79E-5
Colon Cancer															
COLO 205	0.460	1.546	1.214	1.034	0.961	0.667	0.123	69	53	46	19	-73	2.63E-7	1.61E-5	5.60E-5
HCC-2998	0.924	2.667	2.098	1.815	1.924	1.247	0.326	67	51	57	19	-65	1.55E-6	1.67E-5	6.66E-5
HCT-116	0.293	2.198	1.382	0.900	0.831	0.570	0.143	57	32	28	15	-51	1.92E-8	1.66E-5	9.53E-5
HCT-15	0.277	1.895	1.667	1.389	1.117	0.615	0.122	86	69	52	21	-56	1.15E-6	1.87E-5	8.32E-5
HT29	0.297	1.538	1.047	0.866	0.893	0.421	0.123	60	46	48	10	-59	5.17E-8	1.40E-5	7.46E-5
KM12	0.459	2.216	1.769	1.387	1.456	0.764	0.103	75	53	57	17	-78	1.48E-6	1.52E-5	5.11E-5
SVW-620	0.270	2.019	1.260	1.098	1.094	0.744	0.094	57	47	47	27	-65	5.15E-8	1.96E-5	6.82E-5
CNS Cancer															
SF-268	0.720	2.196	1.726	1.120	1.090	1.005	0.474	68	27	25	19	-34	2.76E-8	2.29E-5	> 1.00E-4
SF-295	0.857	2.550	1.842	1.398	1.345	1.123	0.387	58	32	29	16	-55	2.05E-8	1.67E-5	8.54E-5
SF-539	0.986	2.744	1.480	1.165	1.117	0.677	0.310	28	10	7	-31	-69	< 1.00E-8	1.55E-6	3.17E-5
SNB-19	0.510	1.956	1.637	0.961	0.868	0.821	0.180	78	31	25	22	-65	3.95E-8	1.78E-5	6.75E-5
SNB-75	0.985	1.641	1.301	1.250	1.161	1.082	0.508	48	40	27	15	-48	< 1.00E-8	1.71E-5	> 1.00E-4
U251	0.290	1.240	0.731	0.554	0.527	0.440	0.113	46	28	25	16	-61	< 1.00E-8	1.60E-5	7.15E-5
Melanoma															
LOX IMVI	0.321	2.247	1.200	0.551	0.577	0.348	0.205	46	12	13	1	-36	< 1.00E-8	1.09E-5	> 1.00E-4
MALME-3M	0.663	1.338	1.149	1.088	1.097	0.601	0.324	72	63	64	-9	-51	1.56E-6	7.46E-6	9.36E-5
M14	0.409	1.757	0.969	0.512	0.460	0.474	0.116	42	8	4	5	-72	< 1.00E-8	1.16E-5	5.21E-5
MDA-MB-435	0.499	2.140	1.541	1.344	1.329	0.676	0.035	63	51	51	11	-93	1.03E-6	1.27E-5	3.85E-5
SK-MEL-2	1.037	1.778	1.713	1.660	1.674	1.023	0.306	91	84	86	-1	-71	2.58E-6	9.65E-6	5.05E-5
SK-MEL-28	0.666	1.810	1.613	1.462	1.459	0.884	0.136	83	70	69	19	-80	2.42E-6	1.56E-5	5.01E-5
SK-MEL-5	0.722	2.282	1.405	1.222	1.294	0.515	0.050	44	32	37	-29	-93	< 1.00E-8	3.64E-6	2.14E-5
UACC-257	0.939	1.880	1.620	1.379	1.368	1.167	0.043	72	47	46	24	-95	7.43E-8	1.59E-5	4.17E-5
UACC-62	0.637	2.367	1.131	0.879	0.912	0.739	0.119	29	14	16	6	-81	< 1.00E-8	1.17E-5	4.37E-5
Ovarian Cancer															
IGROV1	0.456	1.741	1.155	1.148	1.205	0.809	0.367	54	54	58	27	-20	1.85E-6	3.84E-5	> 1.00E-4
OVCAR-3	0.563	1.718	1.420	1.353	1.305	0.662	0.260	74	68	64	9	-54	1.80E-6	1.37E-5	8.66E-5
OVCAR-4	0.707	1.400	1.213	1.248	1.208	0.831	0.562	73	78	72	18	-21	2.57E-6	2.91E-5	> 1.00E-4
OVCAR-5	0.652	1.784	1.617	1.186	1.163	0.818	0.276	85	47	45	15	-58	8.40E-8	1.59E-5	7.82E-5
OVCAR-8	0.473	1.887	1.223	0.847	0.867	0.738	0.327	53	26	28	19	-31	1.30E-8	2.38E-5	> 1.00E-4
NCI/ADR-RES	0.549	1.788	1.650	1.477	0.953	0.729	0.590	89	75	33	14	3	3.88E-7	> 1.00E-4	> 1.00E-4
SK-OV-3	1.031	2.124	1.789	1.539	1.474	1.284	0.028	69	46	41	23	-97	7.00E-8	1.56E-5	4.05E-5
Renal Cancer															
786-0	0.528	2.134	0.941	0.690	0.650	0.523	0.241	26	10	8	-1	-54	< 1.00E-8	7.57E-6	8.25E-5
A498	1.629	2.440	2.171	2.141	2.087	1.793	0.261	67	63	56	20	-84	1.50E-6	1.56E-5	4.72E-5
ACHN	0.583	2.169	1.112	0.808	0.717	0.658	0.185	33	14	8	5	-68	< 1.00E-8	1.16E-5	5.61E-5
RXF 393	0.805	1.520	1.176	1.043	0.975	0.793	0.308	52	33	24	-1	-62	1.26E-8	8.73E-6	6.37E-5
SN12C	0.617	2.180	1.808	1.035	0.840	0.738	0.411	76	27	14	8	-33	3.38E-8	1.54E-5	> 1.00E-4
TK-10	1.095	1.865	1.808	1.720	1.735	1.544	0.335	93	81	83	58	-69	1.16E-5	2.86E-5	7.05E-5
UO-31	0.718	1.999	1.877	1.193	1.087	0.921	0.286	90	37	29	16	-60	5.72E-8	1.61E-5	7.35E-5
Prostate Cancer															
PC-3	0.467	1.766	1.305	1.275	1.263	0.566	0.309	64	62	61	8	-34	1.62E-6	1.52E-5	> 1.00E-4
DU-145	0.449	1.882	1.304	0.827	0.826	0.727	0.297	60	26	26	19	-34	1.95E-8	2.31E-5	> 1.00E-4
Breast Cancer															
MCF7	0.330	2.207	0.773	0.693	0.698	0.495	0.219	24	19	20	9	-34	< 1.00E-8	1.61E-5	> 1.00E-4
MDA-MB-231/ATCC	0.523	1.521	1.359	1.307	1.262	0.714	0.352	84	78	74	19	-33	2.73E-6	2.33E-5	> 1.00E-4
HS 578T	1.046	1.951	1.831	1.857	1.870	1.490	0.882	87	90	91	49	-16	9.48E-6	5.72E-5	> 1.00E-4
BT-549	1.465	2.629	2.096	1.982	1.902	1.545	0.809	54	44	38	7	-45	2.68E-8	1.36E-5	> 1.00E-4
T-47D	0.848	1.764	1.457	1.169	1.129	0.919	0.745	66	35	31	8	-12	3.33E-8	2.45E-5	> 1.00E-4
MDA-MB-468	0.724	1.647	1.520	1.331	1.063	0.879	0.588	86	66	37	17	-19	3.49E-7	2.96E-5	> 1.00E-4

Table SI4. Rotation barriers found for **16-QM** at the B3LYP-D3BJ/6-31+G* level of theory.

Estimated Energy Barriers (kcal/mol)	B3LYP-D3BJ/6-31+G*
C1 – C2	20.6
C3 – C4	1.9
C4 – C5	3.95
C5 – N6	5.0

Table SI5. Crystallographic Data.

Compound	14	Z-16	17	Z-20	E-4-QM	E-12-QM
Formula	C ₃₈ H ₃₅ FeNO ₅	C ₃₁ H ₂₉ FeNO ₃	C ₃₂ H ₃₁ FeNO ₃	C ₃₈ H ₃₅ FeNO ₄	C _{32.5} H ₃₀ FeNO _{4.5}	C _{33.5} H ₃₂ FeNO _{4.5}
<i>F.W.</i> [g mol ⁻¹]	641.52	519.40	533.43	625.52	562.42	576.45
Crystal system	Triclinic	Monoclinic	Monoclinic	Triclinic	Monoclinic	Monoclinic
Space group	<i>P</i> -1	<i>P</i> 21/ <i>c</i>	<i>P</i> 21/ <i>c</i>	<i>P</i> -1	<i>P</i> 2 ₁ / <i>c</i>	<i>C</i> 2/ <i>c</i>
<i>a</i> [Å]	9.0292(3)	11.5642(5)	9.9878(3)	9.1620(5)	16.3306(7)	34.0540(10)
<i>b</i> [Å]	12.4968(4)	24.4529(12)	18.1152(6)	12.7172(6)	8.6413(3)	8.8249(2)
<i>c</i> [Å]	15.9071(6)	8.9855(5)	14.6303(5)	14.8339(7)	18.9232(9)	19.0317(5)
α [°]	111.067(2)	90	90	66.866(2)	90	90
β [°]	95.140(2)	103.184(3)	98.352(2)	83.823(2)	99.148(2)	105.934(2)
γ [°]	101.789(2)	90	90	84.694(2)	90	90
<i>V</i> [Å ³]	1613.27(10)	2473.9(2)	2619.00(15)	1577.78(14)	2636.43(19)	5499.7(3)
<i>Z</i>	2	4	4	2	4	8
<i>T</i> [K]	200(1)	200(1)	200(1)	200(1)	200(1)	200(1)
λ [Å]	0.71073	0.71073	0.71073	0.71073	0.71073	0.71073
GOF	1.036	1.039	1.045	1.009	1.024	1.035

Reference

- (1) Liu, H.; Liu, J.; van Breemen, R. B.; Thatcher, G. R. J.; Bolton, J. L., *Chem. Res. Toxicol.* **2005**, *18*, 162.
- (2) L. Palatinus, G. Chapuis, *Journal of Applied Crystallography* **2007**, *40*, 786–790.
- (3) G. M. Sheldrick, *Acta Crystallographica Section C* **2015**, *71*, 3–8.
- (4) L. J. Farrugia, *Journal of Applied Crystallography* **1999**, *32*, 837–838.
- (5) O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. Puschmann, *Journal of Applied Crystallography* **2009**, *42*, 339–341.
- (6) Frisch M. J., et al.; Gaussian, Inc.: Wallingford, CT, 2017.
- (7) Lee, C.; Yang, W.; Parr, R. G. Development of the Colle-Salvetti Correlation-Energy Formula into a Functional of the Electron Density. *Physical Review B* **1988**, *37* (2), 785.
- (8) Becke, A. D. Density-Functional Thermochemistry. III. The Role of Exact Exchange. *The Journal of Chemical Physics* **1993**, *98* (7), 5648.
- (9) Grimme, S.; Ehrlich, S.; Goerigk, L. Effect of the Damping Function in Dispersion Corrected Density Functional Theory. *J. Comput. Chem.* **2011**, *32* (7), 1456–1465.
- (10) Tomasi, J.; Mennucci, B.; Cammi, R. Quantum Mechanical Continuum Solvation Models. *Chem. Rev.* **2005**, *105* (8), 2999–3094.
- (11) Hehre, W. J.; Ditchfield, R.; Pople, J. A. Self—Consistent Molecular Orbital Methods. XII. Further Extensions of Gaussian—Type Basis Sets for Use in Molecular Orbital Studies of Organic Molecules. *The Journal of Chemical Physics* **1972**, *56* (5), 2257–2261.
- (12) Hariharan, P. C.; Pople, J. A. The Influence of Polarization Functions on Molecular Orbital Hydrogenation Energies. *Theoret. Chim. Acta* **1973**, *28* (3), 213–222.
- (13) Franci, M. M.; Pietro, W. J.; Hehre, W. J.; Binkley, J. S.; Gordon, M. S.; DeFrees, D. J.; Pople, J. A. Self-consistent Molecular Orbital Methods. XXIII. A Polarization-type Basis Set for Second-row Elements. *The Journal of Chemical Physics* **1982**, *77* (7), 3654–3665.
- (14) Dunning, T. H.; Hay, P. J. *Modern Theoretical Chemistry*; Schaefer, H. F., Ed.; Plenum: New York, 1977.
- (15) Hay, P. J.; Wadt, W. R. *Ab Initio* Effective Core Potentials for Molecular Calculations. Potentials for K to Au Including the Outermost Core Orbitals. *The Journal of Chemical Physics* **1985**, *82* (1), 299–310.

- (16) Grimme, S. Semiempirical Hybrid Density Functional with Perturbative Second-Order Correlation. *The Journal of Chemical Physics* **2006**, *124* (3), 034108.
- (17) É. Brémond and C. Adamo, “Seeking for parameter-free double-hybrid functionals: The PBE0-DH model,” *The Journal of Chemical Physics*, **2011**, *135*, 024106.
- (18) Yanai, T.; Tew, D. P.; Handy, N. C. A New Hybrid Exchange–Correlation Functional Using the Coulomb-Attenuating Method (CAM-B3LYP). *Chemical Physics Letters* **2004**, *393* (1–3), 51–57.
- (19) Martin, R. L. Natural Transition Orbitals. *The Journal of Chemical Physics* **2003**, *118* (11), 4775–4777.